ECRY3.1AB-0208

ECRY3.1AB-0208: Single-Dose Oral (Gavage) Toxicity Study in Mice with a 14-Day Observation Period

Final Report

DATA REQUIREMENT(S): European Community Guidelines for the Assessment of Additives in Feeding Stuffs
US FDA Redbook 2000
US EPA Health Effects Test Guidelines
US EPA Microbial Pesticide Test Guidelines

AUTHOR(S): Chandrashekhar K. Korgaonkar, PhD, DABT

STUDY COMPLETION DATE: 9 April 2009

PERFORMING LABORATORY: WIL Research Laboratories, LLC
1407 George Road
Ashland, OH 44805-8946 USA

LABORATORY PROJECT ID: Report Number: WIL-639031
Study Number: WIL-639031
Task Number: T008660-07

SPONSOR: Syngenta Crop Protection, Inc.
410 Swing Road
Greensboro, NC 27409 US

STATEMENTS OF DATA CONFIDENTIALITY CLAIMS

This page intentionally left blank.

GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT

This study, designated WIL-639031, was conducted in compliance with the United States Environmental Protection Agency (EPA) Good Laboratory Practice Standards (40 CFR Part 160), 16 October 1989, the standard operating procedures of WIL Research Laboratories, LLC, and the protocol as approved by the sponsor with the following exception. Analysis was not performed for the dosing formulations.

The protocol was designed to be in general accordance with the requirements for safety studies as defined by the following regulatory authorities:

The European Community (Guidelines for the Assessment of Additives in Feeding Stuffs),

The United States of America Food and Drug Administration (Redbook 2000 Toxicological Principles for the Safety of Food Ingredients),

The United States of America Environmental Protection Agency (Health Effects Test Guidelines),

The United States of America Environmental Protection Agency (Microbial Pesticide Test Guidelines).

April 9, 2009

Chandrashekhar K. Korgaonkar, PhD, DABT **Date**
Study Director
Staff Toxicologist

Performing Laboratory: **WIL Research Laboratories, LLC**
1407 George Road
Ashland, OH 44805-8946 USA

Submitted by

4/9/09

Wendelyn Jones
Regulatory Affairs Manager
Syngenta Seeds, Inc. – Field Crops – NAFTA
3054 East Cornwallis Rd.
PO Box 12257
Research Triangle Park, NC 27709-2257, USA

Representative of the Sponsor

Alaina Sauvé April 9, 2009

Alaina Sauvé, MS
Research Scientist
Syngenta Crop Protection, Inc.
PO Box 18300 Greensboro, NC 27419-8300

FLAGGING STATEMENT

This page intentionally left blank.

QUALITY ASSURANCE STATEMENT

Phases Inspected

Date(s) of Inspection(s)	Phase Inspected	Date(s) Findings Reported to Study Director	Date(s) Findings Reported to Management	Auditor(s)
03-Oct-2008	Necropsy	03-Oct-2008	24-Nov-2008	P.Rusnak
30-Oct-2008 03-Dec-2008	Study Records (N-1)	03-Dec-2008	26-Jan-2009	A.Hyatt L.Goodrich
30-Oct-2008 26-Nov-2008 03-Dec-2008	Study Records (Rx-1)	03-Dec-2008	26-Jan-2009	L.Goodrich A.Hyatt
03-Nov-2008 04-Nov-2008 05-Nov-2008 26-Nov-2008 03-Dec-2008	Study Records (I-1)	03-Dec-2008	26-Jan-2009	L.Goodrich A.Hyatt
01-Dec-2008 09-Dec-2008 15-Dec-2008	Draft Report(Pathology Appendix)	15-Dec-2008	26-Jan-2009	L.Goodrich A.Hyatt
01-Dec-2008 09-Dec-2008 15-Dec-2008	Study Records (H-1)	15-Dec-2008	26-Jan-2009	L.Goodrich A.Hyatt
01-Dec-2008 09-Dec-2008 15-Dec-2008	Study Records (P-1)	15-Dec-2008	26-Jan-2009	L.Goodrich A.Hyatt
09-Dec-2008 10-Dec-2008 15-Dec-2008 16-Dec-2008	Draft Report (without Pathology Appendix)	16-Dec-2008	26-Jan-2009	L.Goodrich A.Hyatt

This study was inspected in accordance with the U.S. EPA Good Laboratory Practice Standards (40 CFR Part 160), the standard operating procedures of WIL Research Laboratories, LLC and the sponsor's protocol and protocol amendments, with the following exception. The data located in Appendix 1 (Certificate of Analysis) were the responsibility

of the sponsor. Quality Assurance findings, derived from the inspections during the conduct of the study and from the inspections of the raw data and draft report, are documented and have been reported to the study director. A status report is submitted to management monthly.

This report accurately reflects the data generated during the study. The methods and procedures used in the study were those specified in the protocol, its amendments and the standard operating procedures of WIL Research Laboratories, LLC.

The raw data, the retention sample and the final report will be stored in the Archives at WIL Research Laboratories, LLC or another location specified by the sponsor.

Quality Assurance Approval

Report Audited By:

Lori J. Goodrich, RQAP-GLP
Group Supervisor, Quality Assurance

9 April 2009
Date

Amber Hyatt
Associate Compliance Specialist

9-April 2009
Date

Report Released By:

Heather L. Johnson, BS, RQAP-GLP
Manager, Quality Assurance

9 Apr 2009
Date

KEY STUDY PERSONNEL AND REPORT SUBMISSION

Report Submitted By:

Chandrashekhar K. Korgaonkar, PhD, DABT — Date: 9 April 2009
Staff Toxicologist, Toxicology
Study Director

Report Prepared By:

for Stephanie C. Eisenhauer, BS — Date: 6 April 2009
Associate Study Analyst

Report Reviewed By:

for Christopher P. Chengelis, PhD, DABT — Date: 6 April 2009
Vice President and
Chief Scientific Officer

Misty R. Lee, BA — Date: 6 April 2009
Group Supervisor,
Study Analysis and Reports

Shawn D. Seidel, PhD, DABT — Date: 6 April 2009
Staff Toxicologist, Toxicology

GENERAL INFORMATION

Contributors

The following contributed to this report in the capacities indicated:

Name	Title
Chandrashekhar K. Korgaonkar, PhD, DABT	Study Director
Sally A. Keets, AS	Senior Operations Manager, Vivarium
Carol A. Kopp, BS, LAT	Manager, Gross Pathology and Developmental Toxicology Laboratory
Teresa D. Morris, BS	Senior Operations Manager, Toxicology
Theresa M. Rafeld, CPhT	Group Manager, Formulations Laboratory
Michael A. Safron, AS, HT (ASCP)^{CM}	Manager, Histology
Bennett J. Varsho, MPH, DABT	Operations Manager, Developmental and Reproductive Toxicology and the Formulations Laboratory
Robert A. Wally, BS, RAC	Manager, Reporting and Regulatory Technical Services
Alaina Sauvé, MS	Sponsor Representative

Study dates

10 September 2008	Study initiation date (protocol signed by study director)
2 September 2008	Experimental starting date (animal receipt)
19 September 2008	Experimental start date (administration of single oral dose; study day 0)
3 October 2008	Scheduled necropsy (study day 14)
7 November 2008	Experimental termination date (last histopathological examination)

Deviations from the guidelines

None

Deviations from the protocol

This study was conducted in accordance with the protocol and protocol amendments, except for the following.

- **Protocol Section 4.1.6** states that the test material was to be stored frozen, with a desiccant. The test material was received frozen on dry ice and was stored frozen without a desiccant.
- **Protocol Section 7.5.1** states that a complete description of the method of test article preparation will be documented in the raw data and discussed in the final report. According to the test article instructions, the pH was to be measured using litmus paper. However, the pH was not taken from the formulation prepared for Group 1 on 19 September 2008.

These deviations did not negatively impact the quality or integrity of the data or the outcome of the study.

Data Retention and Retention of Samples

The sponsor has title to all documentation records, raw data, specimens or other work product generated during the performance of the study. All work product generated by WIL Research Laboratories, LLC, including raw paper data and specimens, are retained in the Archives at WIL Research Laboratories, LLC, as specified in the study protocol.

Reserve samples of the test substance, pertinent electronic storage media and the original final report are retained in the Archives at WIL Research Laboratories, LLC, in compliance with regulatory requirements.

TABLE OF CONTENTS

1.0 EXECUTIVE SUMMARY

1.1 Study design

The test substance, ECRY3.1AB-0208, containing the active ingredient eCry3.1Ab protein (89.6% purity w/w), was administered as a single oral dose via gavage to groups of 5 male and 5 female Crl:CD-1(ICR) mice at a dose level of 0 or 2000 mg active ingredient/ kg body weight. The vehicle, 0.5% (w/v) aqueous carboxymethylcellulose (CMC; medium viscosity grade), was administered to the control group. The dosing formulations were administered at a dose volume of 10 mL/kg for all groups. All animals were euthanized after a 14-day observation period following dosing.

All animals were observed twice daily for mortality and moribundity. Clinical examinations were performed at the time of dosing, approximately 1-2 hours post-dosing and approximately 4-5 hours post-dosing on the day of dose administration (study day 0) and once daily on nondosing days (study days 1-13). Detailed physical examinations were performed weekly. Individual body weights and food consumption were recorded daily during the study. Complete necropsies were conducted on all animals, and selected tissues were examined microscopically from all animals.

1.2 Results

All animals survived the 14-day observation period to scheduled necropsy. There were no test substance-related clinical observations. There were no test substance-related effects on body weight, food consumption. There were no definitive test substance-related macroscopic or microscopic findings.

1.3 Conclusion

The test substance, ECRY3.1AB-0208, containing the active ingredient eCry3.1Ab protein (89.6% purity w/w), administered as a single oral dose at 2000 mg active ingredient/kg body weight to CD-1 mice followed by a 14-day nondosing observation period was well tolerated. All mice survived without clinical signs of distress or impairment, and anatomical pathology results did not identify any specific target organ toxicity. Therefore, based on the parameters evaluated during the study, there was no evidence of toxicity resulting from the administration of ECRY3.1AB-0208.

2.0 INTRODUCTION

2.1 Purpose

The objective of this study was to evaluate the potential toxicity of ECRY3.1AB-0208 when administered as a single dose orally by gavage to mice, followed by a 14-day observation period to assess the reversibility, persistence or delayed occurrence of any toxic effects.

ECRY3.1AB-0208 is a microbially produced, lyophilized test substance containing the eCry3.1Ab protein. The eCry3.1Ab protein is an engineered chimera of modified Cry3A (mCry3A) and Cry1Ab proteins.

2.2 General Information

This report presents the data from "ECRY3.1AB-0208: Single-Dose Oral (Gavage) Toxicity Study in Mice with a 14-Day Observation Period". Due to software spacing constraints, the study title appears as "A Single-Dose of ECRY3.1AB-0208 in Mice" on the report tables.

The following computer protocols were used for data collection during the study:

Computer Protocol	Type of Data Collected
WIL-639031	Main study data
WIL-639031P	Pretest data
WIL-639031U	Nondosing day observations

3.0 MATERIALS AND METHODS

3.1 Test substance

The test substance, ECRY3.1AB-0208, was received from Syngenta Biotechnology, Inc., Research Triangle Park, NC, on 3 September 2008, as follows:

Identification	Quantity Received	Physical Description
ECRY3.1AB-0208 Exp. Date: June 2018 [WIL log no. 8054A]	12 vials	Off-white lyophilized solid

Documentation regarding the purity and stability of the test substance is on file with the sponsor and WIL Research Laboratories LLC. A Certificate of Analysis for the test substance was provided by the sponsor and is presented in Appendix 1. The purity of the test substance for active ingredient eCry3.1Ab protein was 89.6% w/w. The test substance was stored frozen at approximately -20ºC and was considered stable under this condition. A

reserve sample of the test substance (approximately 3 mg) was collected on 9 September 2008, and stored in the Archives of WIL Research Laboratories, LLC.

3.1.1 Vehicle identification

The vehicle used in preparation of the test article formulations and for administration to the control group was 0.5% (w/v) aqueous carboxymethylcellulose (medium viscosity grade), prepared using the following components:

- carboxymethylcellulose (lot no. XQ0929, exp. date: 11 June 2010, received from Spectrum Chemical Manufacturing Corporation, New Brunswick, NJ),
- deionized water (prepared on-site).

3.1.2 Preparation of test substance dosing formulation

The vehicle solution was prepared once on 18 September 2008 (the day before dosing) for administration to the control group (Group 1) and for preparation of the test article formulations. The vehicle was mixed throughout preparation and dose administration procedures.

Dosing formulation was prepared at the concentration indicated in the following table:

Group Number	Test Substance	Dose Level [a] (mg/kg)	Dose Concentration [a] (mg/mL)
2	ECRY3.1AB-0208	2000	200

[a] = Dose level and concentration refer to concentration of active ingredient (adjusted by a factor of 1.116 to account for active ingredient purity in the test substance). Therefore, the dose level of the test substance was 2232 mg/kg and the concentration of the test substance in the dosing formulation was 223.2 mg/mL.

The test article formulation was a weight/volume (test article/vehicle) mixture. The test article formulation was prepared once on 19 September 2008 (the day of dosing) as a single formulation and stored at room temperature. The test article formulations were stirred continuously throughout the preparation and dose administration procedures.

3.1.3 Sampling and analyses

Analyses of dosing formulations were not conducted as part of this study.

3.2 Experimental design

3.2.1 Test system

Crl:CD-1 (ICR) mice from Charles River Laboratories, Inc., Raleigh, NC were used as the test system on this study. This species and strain of animal is recognized as appropriate for short-term toxicity studies. The mouse was used because it is a universally used model for evaluating toxicity of various classes of chemicals and is a widely used species for which significant historical control data are available in the literature and at WIL Research Laboratories, LLC. The animals were approximately 9 weeks old at the initiation of dose administration.

3.2.2 Organization of test groups, dose levels and treatment regimen

The vehicle and test substance formulations were administered as a single oral dose by gavage via syringes of appropriate volume equipped with flexible Teflon®-shafted, stainless steel ball-tipped dosing cannula (Natume, Japan). The dose volume for all groups was 10 mL/kg. Individual doses were based on the study day 0 individual body weights collected after a 3-hour fasting period to provide the correct mg/kg dosage.

The following table represents the study group assignment:

Group Number	Test Substance	Dose Level (mg/kg/day)[b]	Dose Volume (mL/kg)	Number of Animals[c]	
				Males	Females
1	Vehicle[a]	0	0	5	5
2	ECRY3.1AB-0208	2000	200	5	5

[a] = Vehicle was 0.5% carboxymethylcellulose
[b] = Dose level and concentration refer to concentration of active ingredient (adjusted by a factor of 1.116 to account for active ingredient purity in the test substance). Therefore, the dose level of the test substance was 2232 mg/kg and the concentration of the test substance in the dosing formulation was 223.2 mg/mL.
[c] = All animals/sex/group were euthanized following 14 days of observation.

The single dose level of 2000 mg/kg was selected because it represents a limit dose for this type of study (OECD 2001; U.S. EPA 2002).

The selected route of administration for this study was oral (gavage) since the oral route represents a likely route of human exposure and other mammalian exposure to the test protein. The number of animals selected for this study was sufficient to provide adequate statistical evaluation of the data and was the minimum required to achieve the objectives of the study.

3.2.3 Animal receipt and acclimation/pretest period

Sixteen male and 15 female Crl:CD-1 (ICR) mice were received in good health on 2 September 2008, from Charles River Laboratories, Inc., Raleigh, NC. The animals were approximately 49 days old at receipt. Each animal was examined by a qualified technician on the day of receipt and weighed 3 days later. Each animal was uniquely identified by a programmable microchip containing the permanent identification number. The microchip was implanted subcutaneously in the dorsoscapular region for each individual animal during the acclimation period. All animals were housed for a 17-day acclimation/pretest period. During this period, each animal was observed twice daily for mortality and changes in general appearance or behavior.

Pretest data collection began on 5 September 2008. Individual body weights were recorded and detailed physical examinations were performed periodically during the pretest period. Food consumption data were also recorded for pretest animals prior to the initiation of dose administration. Pretest clinical observations are presented in Appendix 2.

3.2.4 Animal housing

Upon arrival, all animals were housed 3 per cage by sex for approximately 3 days. Thereafter, all animals were housed individually in clean, stainless steel, wire mesh cages suspended above cage board. Animals were maintained in accordance with the *Guide for the Care and Use of Laboratory Animals* (National Research Council, 1996). The animal facilities at WIL Research Laboratories, LLC are accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International).

3.2.5 Diet, drinking water and maintenance

The basal diet used in this study, PMI Nutrition International, LLC, Certified Rodent LabDiet® 5002 (meal), is a certified feed with appropriate analyses performed by the manufacturer and provided to WIL Research Laboratories, LLC. Reverse osmosis treated (on site) drinking water, delivered by an automatic watering system, and the basal diet were provided ad libitum during the observation period. On study day 0, the diet was removed approximately 3 hours prior to dosing and was returned approximately 1-2 hours post-dosing, after the completion of the 1-2 hour post-dosing clinical observation. Municipal water supplying the facility was analyzed for contaminants according to the standard operating procedures. The results of the diet and water analyses are maintained at WIL Research Laboratories, LLC. No contaminants were present in animal feed or water at concentrations sufficient to interfere with the objectives of this study.

3.2.6 Environmental conditions

All animals were housed throughout the acclimation period and during the study in an environmentally controlled room. The room temperature and humidity controls were set to maintain environmental conditions of 71 ± 5°F (22 ± 3ºC) and 50 ± 20% relative humidity.

Room temperature and relative humidity were controlled and monitored using the Metasys® DDC Electronic Environmental control system. These data were recorded approximately hourly and are summarized in Appendix 3. Actual mean daily temperature ranged from 70.9°F to 71.9°F (21.6°C to 22.1°C) and mean daily relative humidity ranged from 43.2% to 55.3% during the study. Fluorescent lighting provided illumination for a 12 hour light (0600 hours to 1800 hours)/12 hour dark photoperiod. Air handling units were set to provide a minimum of 10 fresh air changes per hour.

3.2.7 Assignment of animals to treatment groups

On 17 September 2008 (2 days prior to the day of dosing), all available mice were weighed and examined in detail for physical abnormalities. These data were collected using the WIL Toxicology Data Management System (WTDMS™) and reviewed by the study director. The animals judged suitable for assignment to the study were selected for use in a computerized randomization procedure. A printout containing the animal numbers, corresponding body weights and individual group assignments was generated based on body weight stratification in a block design. The animals were then arranged into groups according to the printout. Individual body weights at randomization were within ± 20% of the mean for each sex. Each group consisted of 5 males and 5 females. Individual body weights ranged from 28.5 g to 34.1 g for males and from 23.3 g to 27.2 g for females at the initiation of dosing.

3.3 *Ante mortem* investigations

3.3.1 Clinical observations and survival

All animals were observed twice daily, once in the morning and once in the afternoon, for mortality and moribundity.

Clinical examinations were performed at the time of dose administration, approximately 1 to 2 hours following dose administration and approximately 4 to 5 hours following dose administration. During the recovery period, the animals were observed once daily. The absence or presence of findings was recorded for individual animals at the scheduled intervals. Detailed physical examinations were conducted on all animals weekly, beginning 1 week prior to test substance administration and prior to the scheduled necropsy. Daily observations during the nondosing period were not conducted on days that the detailed physical examinations were performed.

3.3.2 Body weights

Individual body weights were recorded weekly during the pretest period, at randomization, just prior to dosing (after 3 hours of fasting) and daily during the observation period. Mean body weights and mean body weight changes were calculated for the corresponding intervals.

3.3.3 Food consumption

Individual food consumption was recorded weekly during the pretest period and daily during the study. Food intake was calculated as g/animal/day for the corresponding body weight intervals. When food consumption could not be measured for a given interval (due to spillage, weighing error, obvious erroneous value, etc.), the appropriate interval was footnoted as "NA" (Not Applicable) on the individual tables.

3.4 *Post mortem* investigations

3.4.1 Macroscopic examination

A complete necropsy was conducted on all animals. Animals were euthanized by carbon dioxide anesthesia and exsanguinated. The necropsies included, but were not limited to, examination of the external surface, all orifices, and the cranial, thoracic, abdominal and pelvic cavities, including viscera. The following tissues and organs were collected and placed in 10% neutral buffered formalin (except as noted):

Adrenals (2)
Aorta
Bone with marrow
  Femur with joint
  Sternum
Bone marrow smear [a]
Brain
  Cerebrum (2 levels)
  Cerebellum with medulla/pons
Cervix
Epididymides (2) [b]
Eyes with optic nerve (2) [c]
Gallbladder
Gastrointestinal tract
  Esophagus *
  Stomach *
  Duodenum *
  Jejunum *
  Peyer's patches *
  Ileum *
  Cecum *
  Colon *
  Rectum *
Heart
Kidneys (2)
Liver
Lungs (fixed by inflation with fixative)
Lymph nodes
  Mandibular *
  Mesenteric *
Ovaries (2) with oviducts [d]
Pancreas
Peripheral nerve (sciatic)
Pituitary
Prostate
Salivary glands [mandibular (2)]
Seminal vesicles (2)
Skeletal muscle (rectus femoris)
Skin with mammary gland [e]
Spinal cord (cervical, thoracic, lumbar)
Spleen *
Testes (2) [b]
Thymus *
Thyroid [with parathyroids, if present (2)] [d]
Trachea
Urinary bladder
Uterus
Vagina
Gross lesions (when possible) *

[a] - Bone marrow smears were taken at necropsy; not placed in formalin; to be examined only if scientifically warranted.
[b] - Fixed in Bouin's solution
[c] - Fixed in Davidson's solution
[d] - Parathyroids and oviducts were examined histologically if in the plane of section and in all cases when a gross lesion was present.
[e] - For females; a corresponding section of skin was taken from the same anatomic area for males.
* - Tissues to be processed for histopathological examination from all animals at the scheduled necropsy.

3.4.2 Slide preparation and microscopic examination

After fixation, protocol specified tissues were trimmed according to standard operating procedures and the protocol. Trimmed tissues were processed into paraffin blocks, sectioned at 4 to 8 microns, mounted on glass microscope slides and stained with hematoxylin and eosin.

Microscopic examination was performed on all tissues noted with an asterisk (*) listed in Section 3.4.1 from all animals at the scheduled necropsy. The remaining tissues were stored

in 10% neutral-buffered formalin (except as noted) for possible future histopathological examination. Missing tissues were identified as not found at necropsy, lost at necropsy, lost during processing or other designations as appropriate. Tissues may appear on the report tables as not examined due to the tissue not being in the plane of section, not present at trimming, etc. Microscopic examination was performed by Ann Radovsky, DVM, PhD, DACVP, DABT, WIL Research Laboratories, LLC (Appendix 4).

3.5 Data evaluation

All statistical tests were performed using appropriate computing devices or programs. Analyses were conducted using two-tailed tests (except as noted otherwise) for minimum significance levels of 1% and 5%, comparing the test substance-treated group to the control group by sex. Each mean was presented with the standard deviation (S.D.) and the number of animals (N) used to calculate the mean. Statistical analyses were not conducted if the number of animals was 2 or less. Due to the different rounding conventions inherent in the types of software used, the means and standard deviations on the summary and individual tables may differ by ±1 in the last significant figure.

Body weight, body weight change and food consumption data were subjected to a parametric one way analysis of variance (ANOVA) (Snedecor and Cochran, 1980) to determine intergroup differences. If the ANOVA revealed statistically significant ($p < 0.05$) intergroup variance, Dunnett's test (Dunnett, 1964) was used to compare the test substance-treated group to the control group.

4.0 RESULTS AND DISCUSSION

4.1 Clinical observations and survival

Summary Data: Tables 1, 2, 3, 4
Individual Data: Tables A1, A2, A3, A4, A5

All animals survived to the scheduled necropsy. There were no test substance-related clinical observations.

The observation of yellow material near the urogenital area was noted for one male in the test substance-treated group. This observation was not considered test substance-related as it was noted in a single animal during the observation (nondosing) period on study days 8 and 9. All clinical findings in the test substance-treated groups were limited to single animals and/or were common findings for laboratory mice of this age and strain.

4.2 Body weights

Summary Data: Tables 5, 6, 7; Figures 1, 2
Individual Data: Tables A6, A7, A8

Body weights were unaffected by test substance administration.

Statistically significantly higher mean body weight gain was noted for the 2000 mg/kg group males on study days 3 to 4 and 13 to 14 compared to the control group. This difference in body weight gain was considered incidental and not related to test substance administration because the magnitude of the change was very small. There were no differences in cumulative body weight gains for males at any time.

Statistically significantly lower mean body weight gain was noted for the 2000 mg/kg females on study days 2 to 3 and 9 to 10. This difference in body weight gain was considered incidental and not related to test substance administration because the magnitude of the change was very small. The 2000 mg/kg group females had a statistically significantly higher cumulative body weight gain (from study day 0 to 2) compared to the 0 mg/kg group females, but at no other interval during the study.

4.3 Food consumption

Summary Data: Table 8
Individual Data: Table A9

Food consumption was unaffected by test substance administration.

Statistically significantly higher mean food consumption was noted for the 2000 mg/kg group males on study days 8-9 and 12-13. This difference in food consumption was considered

incidental and not related to test substance administration because the magnitude of the change was small and no changes in food consumption were noted for the remaining study intervals.

4.4 Anatomic pathology

4.4.1 Macroscopic examination

Summary Data: Table 9
Individual Data: Table A10
Pathology Report: Appendix 4

Review of the gross necropsy observations revealed no observations that were considered to be associated with administration of the test substance.

4.4.2 Microscopic examination

Summary Data: Table 10
Individual Data: Table A10
Pathology Report: Appendix 4

All histologic changes were considered to be incidental findings or related to some aspect of experimental manipulation other than administration of the test substance. There was no test substance-related alteration in the prevalence, severity or histologic character of those incidental tissue alterations.

5.0 CONCLUSIONS

The test substance, ECRY3.1AB-0208, containing the active ingredient eCry3.1Ab protein (89.6% purity w/w), administered as a single oral dose at 2000 mg active ingredient/kg body weight to CD-1 mice followed by a 14-day nondosing observation period was well tolerated. All mice survived without clinical signs of distress or impairment, and anatomical pathology results did not identify any specific target organ toxicity. Therefore, based on the parameters evaluated during the study, there was no evidence of toxicity resulting from the administration of ECRY3.1AB-0208.

6.0 REFERENCES

Dunnett, C.W. New tables for multiple comparisons with a control. *Biometrics* **1964,** *20,* 482-491.

National Research Council. *Guide for the Care and Use of Laboratory Animals,* Institute of Laboratory Animal Resources, Commission on Life Sciences; National Academy Press: Washington, DC, **1996**.

OECD (2001) OECD Guideline Test Guideline 420 Acute Oral Toxicity: Fixed Dose Procedure. http://iccvam.niehs.nih.gov/SuppDocs/FedDocs/OECD/OECD_GL420.pdf.

Snedecor, G.W.; Cochran, W.G. One Way Classifications; Analysis of Variance. In *Statistical Methods*, 7th ed.; The Iowa State University Press: Ames, IA, **1980**; pp 215-237.

U.S. EPA (2002) Health Effects Test Guidelines – OPPTS 870.1100 – Acute Oral Toxicity. http://www.epa.gov/opptsfrs/publications/OPPTS_Harmonized/870_Health_Effects_Test Guidelines/Series/Revised 870r-1100.pdf

TABLES SECTION

TABLE 1

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 1

SPONSOR:SYNGENTA SUMMARY OF SURVIVAL AND DISPOSITION

MALES

GROUP :	1				2			
DAY	LIVE	FD	EE	SE	LIVE	FD	EE	SE
0	5	0	0	0	5	0	0	0
1	5	0	0	0	5	0	0	0
2	5	0	0	0	5	0	0	0
3	5	0	0	0	5	0	0	0
4	5	0	0	0	5	0	0	0
5	5	0	0	0	5	0	0	0
6	5	0	0	0	5	0	0	0
7	5	0	0	0	5	0	0	0
8	5	0	0	0	5	0	0	0
9	5	0	0	0	5	0	0	0
10	5	0	0	0	5	0	0	0
11	5	0	0	0	5	0	0	0
12	5	0	0	0	5	0	0	0
13	5	0	0	0	5	0	0	0
14	0	0	0	5	0	0	0	5

DAY = DAY OF STUDY FD = FOUND DEAD EE = EUTHANIZED IN EXTREMIS SE = SCHEDULED EUTHANASIA

1- 0 MG/KG 2- 2000 MG/KG

TABLE 1

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 2

SPONSOR:SYNGENTA SUMMARY OF SURVIVAL AND DISPOSITION

FEMALES

GROUP :	1				2			
DAY	LIVE	FD	EE	SE	LIVE	FD	EE	SE
0	5	0	0	0	5	0	0	0
1	5	0	0	0	5	0	0	0
2	5	0	0	0	5	0	0	0
3	5	0	0	0	5	0	0	0
4	5	0	0	0	5	0	0	0
5	5	0	0	0	5	0	0	0
6	5	0	0	0	5	0	0	0
7	5	0	0	0	5	0	0	0
8	5	0	0	0	5	0	0	0
9	5	0	0	0	5	0	0	0
10	5	0	0	0	5	0	0	0
11	5	0	0	0	5	0	0	0
12	5	0	0	0	5	0	0	0
13	5	0	0	0	5	0	0	0
14	0	0	0	5	0	0	0	5

DAY = DAY OF STUDY FD = FOUND DEAD EE = EUTHANIZED IN EXTREMIS SE = SCHEDULED EUTHANASIA

1- 0 MG/KG 2- 2000 MG/KG

PSURVv4.09
11/05/2008

TABLE 2 (DETAILED PHYSCIAL EXAMINATIONS/DISPOSITIONS)
PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 1
SPONSOR:SYNGENTA SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- M A L E -----

TABLE RANGE:	DAY 000 TO DAY 014	
GROUP:	1	2
NORMAL		
-NO SIGNIFICANT CLINICAL OBSERVATIONS	13/ 5	13/ 5
DISPOSITION		
-PRIMARY NECROPSY (DAY 14)	5/ 5	5/ 5
EYES/EARS/NOSE		
-ABNORMAL PUPIL POSITION LEFT EYE	2/ 1	0/ 0
BODY/INTEG III		
-DRIED YELLOW MATERIAL UROGENITAL AREA	0/ 0	1/ 1
-DRIED YELLOW MATERIAL ANOGENITAL AREA	0/ 0	1/ 1

1- 0 MG/KG 2- 2000 MG/KG

TABLE 2 (DETAILED PHYSCIAL EXAMINATIONS/DISPOSITIONS)
PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 2
SPONSOR:SYNGENTA SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	DAY 000 TO DAY 014	
GROUP:	1	2
NORMAL		
-NO SIGNIFICANT CLINICAL OBSERVATIONS	15/ 5	15/ 5
DISPOSITION		
-PRIMARY NECROPSY (DAY 14)	5/ 5	5/ 5

1- 0 MG/KG 2- 2000 MG/KG

PCSUv4.07
11/05/2008

TABLE 3 (DOSING DAY OBSERVATIONS)

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 1

SPONSOR:SYNGENTA SUMMARY OF POST-DOSE FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

	----- M A L E -----	
TABLE RANGE:	DAY 0	
GROUP:	1	2
NORMAL		
TIME OF DOSE		
-NO SIGNIFICANT CLINICAL OBSERVATIONS	5/5	5/5
1-2 HOURS POST DOSING		
-NO SIGNIFICANT CLINICAL OBSERVATIONS	5/5	5/5
4-5 HOURS POST DOSING		
-NO SIGNIFICANT CLINICAL OBSERVATIONS	5/5	5/5

1- 0 MG/KG 2- 2000 MG/KG

TABLE 3 (DOSING DAY OBSERVATIONS)

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 2

SPONSOR:SYNGENTA SUMMARY OF POST-DOSE FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

	----- F E M A L E -----	
TABLE RANGE:	DAY 0	
GROUP:	1	2
NORMAL		
TIME OF DOSE		
-NO SIGNIFICANT CLINICAL OBSERVATIONS	5/5	5/5
1-2 HOURS POST DOSING		
-NO SIGNIFICANT CLINICAL OBSERVATIONS	5/5	5/5
4-5 HOURS POST DOSING		
-NO SIGNIFICANT CLINICAL OBSERVATIONS	5/5	5/5

1- 0 MG/KG 2- 2000 MG/KG

PPDTSUv1.39
11/05/2008

TABLE 4 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639031U — A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE — PAGE 1

SPONSOR:SYNGENTA — SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

	----- M A L E -----	
TABLE RANGE:	DAY 001 TO DAY 013	
GROUP:	1	2
NORMAL		
-NO SIGNIFICANT CLINICAL OBSERVATIONS	60/ 5	58/ 5
BODY/INTEG III		
-DRIED YELLOW MATERIAL UROGENITAL AREA	0/ 0	2/ 1

1- 0 MG/KG 2- 2000 MG/KG

TABLE 4 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639031U — A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE — PAGE 2

SPONSOR:SYNGENTA — SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

	----- F E M A L E -----	
TABLE RANGE:	DAY 001 TO DAY 013	
GROUP:	1	2
NORMAL		
-NO SIGNIFICANT CLINICAL OBSERVATIONS	60/ 5	60/ 5

1- 0 MG/KG 2- 2000 MG/KG

PCSUv4.07
11/05/2008
R:11/05/2008

TABLE 5

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 1

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHTS [G]

		MALES	
	GROUP:	0 MG/KG	2000 MG/KG
DAY -14			
	MEAN	28.2	28.1
	S.D.	2.69	1.38
	N	5	5
-8			
	MEAN	30.1	30.2
	S.D.	2.68	1.74
	N	5	5
-2			
	MEAN	31.9	32.1
	S.D.	2.62	1.74
	N	5	5
0			
	MEAN	30.9	31.2
	S.D.	2.36	1.62
	N	5	5
1			
	MEAN	31.4	32.3
	S.D.	2.33	1.73
	N	5	5

None significantly different from control group

TABLE 5

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 2

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHTS [G]

		MALES	
	GROUP:	0 MG/KG	2000 MG/KG
DAY 2			
	MEAN	31.7	31.5
	S.D.	1.96	2.65
	N	5	5
3			
	MEAN	31.9	32.0
	S.D.	2.02	1.40
	N	5	5
4			
	MEAN	32.3	32.9
	S.D.	2.04	1.74
	N	5	5
5			
	MEAN	32.3	32.6
	S.D.	1.88	1.74
	N	5	5
6			
	MEAN	31.9	32.0
	S.D.	1.64	1.54
	N	5	5

None significantly different from control group

TABLE 5

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 3

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHTS [G]

MALES

GROUP:		0 MG/KG	2000 MG/KG
DAY 7	MEAN	32.8	32.7
	S.D.	1.82	1.60
	N	5	5
8	MEAN	32.7	32.3
	S.D.	1.83	1.79
	N	5	5
9	MEAN	33.0	32.9
	S.D.	1.88	1.48
	N	5	5
10	MEAN	33.0	32.7
	S.D.	2.08	1.11
	N	5	5
11	MEAN	32.4	32.6
	S.D.	1.81	1.31
	N	5	5

None significantly different from control group

TABLE 5

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 4

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHTS [G]

MALES

GROUP:	0 MG/KG	2000 MG/KG
DAY 12		
MEAN	33.1	33.5
S.D.	1.87	1.57
N	5	5
13		
MEAN	33.0	33.1
S.D.	1.73	1.46
N	5	5
14		
MEAN	32.7	33.6
S.D.	1.68	1.40
N	5	5

None significantly different from control group

TABLE 5

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 5

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHTS [G]

FEMALES

GROUP:		0 MG/KG	2000 MG/KG
DAY -14			
	MEAN	22.1	22.2
	S.D.	1.19	1.43
	N	5	5
-8			
	MEAN	23.9	24.3
	S.D.	1.23	1.57
	N	5	5
-2			
	MEAN	25.6	25.4
	S.D.	1.90	1.23
	N	5	5
0			
	MEAN	24.5	24.2
	S.D.	1.63	1.44
	N	5	5
1			
	MEAN	25.2	25.1
	S.D.	1.77	1.84
	N	5	5

None significantly different from control group

TABLE 5

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 6

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHTS [G]

		FEMALES	
	GROUP:	0 MG/KG	2000 MG/KG
DAY 2			
	MEAN	24.1	25.5
	S.D.	1.92	1.33
	N	5	5
3			
	MEAN	26.0	25.5
	S.D.	2.20	1.32
	N	5	5
4			
	MEAN	26.3	25.8
	S.D.	1.77	1.63
	N	5	5
5			
	MEAN	26.0	25.7
	S.D.	1.59	1.85
	N	5	5
6			
	MEAN	25.9	25.5
	S.D.	1.87	1.69
	N	5	5

None significantly different from control group

TABLE 5

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 7

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHTS [G]

		FEMALES	
	GROUP:	0 MG/KG	2000 MG/KG
DAY 7			
	MEAN	26.5	26.0
	S.D.	2.31	1.62
	N	5	5
8			
	MEAN	26.2	26.1
	S.D.	1.73	1.57
	N	5	5
9			
	MEAN	26.4	26.3
	S.D.	1.85	2.05
	N	5	5
10			
	MEAN	26.8	26.0
	S.D.	1.69	2.08
	N	5	5
11			
	MEAN	26.6	25.6
	S.D.	1.77	1.49
	N	5	5

None significantly different from control group

TABLE 5

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 8

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHTS [G]

	FEMALES	
GROUP:	0 MG/KG	2000 MG/KG
DAY 12		
MEAN	27.0	26.8
S.D.	1.29	1.85
N	5	5
13		
MEAN	27.2	26.9
S.D.	1.57	2.04
N	5	5
14		
MEAN	26.7	26.9
S.D.	1.84	1.72
N	5	5

None significantly different from control group

PBFSTv5.28
11/05/2008

TABLE 6

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 1
SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHT CHANGES [G]

	MALES	
GROUP:	0 MG/KG	2000 MG/KG
DAY -14 TO -8		
MEAN	1.9	2.1
S.D.	0.77	0.46
N	5	5
-8 TO -2		
MEAN	1.8	1.9
S.D.	0.79	0.56
N	5	5
-2 TO 0		
MEAN	-1.1	-0.9
S.D.	0.44	0.43
N	5	5
0 TO 1		
MEAN	0.6	1.1
S.D.	0.31	0.74
N	5	5
1 TO 2		
MEAN	0.2	-0.9
S.D.	0.70	1.70
N	5	5

None significantly different from control group

TABLE 6

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 2

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHT CHANGES [G]

		MALES	
	GROUP:	0 MG/KG	2000 MG/KG
DAY	2 TO 3		
	MEAN	0.3	0.6
	S.D.	0.40	1.75
	N	5	5
	3 TO 4		
	MEAN	0.3	0.9*
	S.D.	0.11	0.49
	N	5	5
	4 TO 5		
	MEAN	0.0	-0.3
	S.D.	0.24	0.22
	N	5	5
	5 TO 6		
	MEAN	-0.3	-0.7
	S.D.	0.46	0.35
	N	5	5
	6 TO 7		
	MEAN	0.8	0.7
	S.D.	0.42	0.49
	N	5	5

* = Significantly different from the control group at 0.05 using Dunnett’s test

TABLE 6

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHT CHANGES [G]

	MALES	
GROUP:	0 MG/KG	2000 MG/KG
DAY 7 TO 8		
MEAN	0.0	-0.4
S.D.	0.41	0.48
N	5	5
8 TO 9		
MEAN	0.3	0.6
S.D.	0.37	0.42
N	5	5
9 TO 10		
MEAN	-0.1	-0.3
S.D.	0.39	0.50
N	5	5
10 TO 11		
MEAN	-0.6	-0.1
S.D.	0.44	0.23
N	5	5
11 TO 12		
MEAN	0.7	1.0
S.D.	0.38	0.63
N	5	5

None significantly different from control group

TABLE 6

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 4

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHT CHANGES [G]

	MALES	
GROUP:	0 MG/KG	2000 MG/KG
DAY 12 TO 13		
MEAN	-0.1	-0.5
S.D.	0.49	0.30
N	5	5
13 TO 14		
MEAN	-0.3	0.6**
S.D.	0.24	0.43
N	5	5

** = Significantly different from the control group at 0.01 using Dunnett’s test

TABLE 6

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 5

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHT CHANGES [G]

	FEMALES	
GROUP:	0 MG/KG	2000 MG/KG
DAY -14 TO -8		
MEAN	1.8	2.1
S.D.	0.83	0.94
N	5	5
-8 TO -2		
MEAN	1.8	1.2
S.D.	0.84	0.59
N	5	5
-2 TO 0		
MEAN	-1.2	-1.2
S.D.	0.55	0.38
N	5	5
0 TO 1		
MEAN	0.8	1.0
S.D.	0.68	0.49
N	5	5
1 TO 2		
MEAN	-1.1	0.3
S.D.	1.01	1.06
N	5	5

None significantly different from control group

TABLE 6

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 6

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHT CHANGES [G]

		FEMALES	
GROUP:		0 MG/KG	2000 MG/KG
DAY	2 TO 3		
	MEAN	1.9	0.0**
	S.D.	0.68	0.80
	N	5	5
	3 TO 4		
	MEAN	0.3	0.3
	S.D.	0.77	0.38
	N	5	5
	4 TO 5		
	MEAN	-0.3	-0.1
	S.D.	0.36	0.41
	N	5	5
	5 TO 6		
	MEAN	-0.1	-0.2
	S.D.	0.53	0.37
	N	5	5
	6 TO 7		
	MEAN	0.7	0.5
	S.D.	0.58	0.31
	N	5	5

** = Significantly different from the control group at 0.01 using Dunnett’s test

TABLE 6

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 7

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHT CHANGES [G]

	FEMALES	
GROUP:	0 MG/KG	2000 MG/KG
DAY 7 TO 8		
MEAN	-0.3	0.1
S.D.	0.64	0.58
N	5	5
8 TO 9		
MEAN	0.2	0.2
S.D.	0.61	0.56
N	5	5
9 TO 10		
MEAN	0.4	-0.3*
S.D.	0.49	0.32
N	5	5
10 TO 11		
MEAN	-0.2	-0.4
S.D.	0.45	0.70
N	5	5
11 TO 12		
MEAN	0.4	1.2
S.D.	0.80	0.66
N	5	5

* = Significantly different from the control group at 0.05 using Dunnett’s test

TABLE 6

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 8

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHT CHANGES [G]

	FEMALES	
GROUP:	0 MG/KG	2000 MG/KG
DAY 12 TO 13		
MEAN	0.2	0.1
S.D.	0.56	0.56
N	5	5
13 TO 14		
MEAN	-0.5	0.0
S.D.	0.57	0.70
N	5	5

None significantly different from control group

PBFSTv5.28
11/05/2008

TABLE 7

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 1

SPONSOR:SYNGENTA SUMMARY OF CUMULATIVE BODY WEIGHT CHANGES [G]

		MALES	
GROUP:		0 MG/KG	2000 MG/KG
DAY	0 TO 1		
	MEAN	0.6	1.1
	S.D.	0.31	0.74
	N	5	5
	0 TO 2		
	MEAN	0.8	0.3
	S.D.	0.72	1.47
	N	5	5
	0 TO 3		
	MEAN	1.1	0.8
	S.D.	0.44	0.54
	N	5	5
	0 TO 4		
	MEAN	1.4	1.7
	S.D.	0.41	0.56
	N	5	5
	0 TO 5		
	MEAN	1.4	1.4
	S.D.	0.63	0.46
	N	5	5

None significantly different from control group

TABLE 7

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 2

SPONSOR:SYNGENTA SUMMARY OF CUMULATIVE BODY WEIGHT CHANGES [G]

		MALES	
GROUP:		0 MG/KG	2000 MG/KG
DAY	0 TO 6		
	MEAN	1.1	0.8
	S.D.	0.85	0.63
	N	5	5
	0 TO 7		
	MEAN	1.9	1.5
	S.D.	0.61	0.59
	N	5	5
	0 TO 8		
	MEAN	1.9	1.1
	S.D.	0.79	0.75
	N	5	5
	0 TO 9		
	MEAN	2.2	1.7
	S.D.	1.06	0.48
	N	5	5
	0 TO 10		
	MEAN	2.1	1.5
	S.D.	1.23	0.72
	N	5	5

None significantly different from control group

TABLE 7

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 3

SPONSOR:SYNGENTA SUMMARY OF CUMULATIVE BODY WEIGHT CHANGES [G]

		MALES	
GROUP:		0 MG/KG	2000 MG/KG
DAY	0 TO 11		
	MEAN	1.5	1.4
	S.D.	0.97	0.69
	N	5	5
	0 TO 12		
	MEAN	2.3	2.3
	S.D.	1.10	0.73
	N	5	5
	0 TO 13		
	MEAN	2.1	1.9
	S.D.	1.33	0.84
	N	5	5
	0 TO 14		
	MEAN	1.8	2.4
	S.D.	1.48	0.89
	N	5	5

None significantly different from control group

TABLE 7

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 4

SPONSOR:SYNGENTA SUMMARY OF CUMULATIVE BODY WEIGHT CHANGES [G]

		FEMALES	
GROUP:		0 MG/KG	2000 MG/KG
DAY	0 TO 1		
	MEAN	0.8	1.0
	S.D.	0.68	0.49
	N	5	5
	0 TO 2		
	MEAN	-0.4	1.3*
	S.D.	1.09	0.99
	N	5	5
	0 TO 3		
	MEAN	1.5	1.3
	S.D.	1.12	0.50
	N	5	5
	0 TO 4		
	MEAN	1.8	1.6
	S.D.	0.58	0.44
	N	5	5
	0 TO 5		
	MEAN	1.5	1.5
	S.D.	0.82	0.47
	N	5	5

* = Significantly different from the control group at 0.05 using Dunnett’s test

TABLE 7

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 5

SPONSOR:SYNGENTA SUMMARY OF CUMULATIVE BODY WEIGHT CHANGES [G]

		FEMALES	
GROUP:		0 MG/KG	2000 MG/KG
DAY	0 TO 6		
	MEAN	1.4	1.3
	S.D.	0.97	0.55
	N	5	5
	0 TO 7		
	MEAN	2.0	1.8
	S.D.	1.00	0.78
	N	5	5
	0 TO 8		
	MEAN	1.8	1.9
	S.D.	0.60	0.50
	N	5	5
	0 TO 9		
	MEAN	1.9	2.1
	S.D.	1.09	0.69
	N	5	5
	0 TO 10		
	MEAN	2.3	1.8
	S.D.	0.82	0.70
	N	5	5

None significantly different from control group

TABLE 7

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 6

SPONSOR:SYNGENTA SUMMARY OF CUMULATIVE BODY WEIGHT CHANGES [G]

		FEMALES	
GROUP:		0 MG/KG	2000 MG/KG
DAY	0 TO 11		
	MEAN	2.1	1.4
	S.D.	1.14	0.26
	N	5	5
	0 TO 12		
	MEAN	2.5	2.6
	S.D.	0.81	0.62
	N	5	5
	0 TO 13		
	MEAN	2.7	2.7
	S.D.	1.12	0.66
	N	5	5
	0 TO 14		
	MEAN	2.2	2.7
	S.D.	0.87	0.50
	N	5	5

None significantly different from control group

PBFSTv5.28
11/05/2008

TABLE 8

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 1

SPONSOR:SYNGENTA SUMMARY OF FOOD CONSUMPTION [G/ANIMAL/DAY]

	MALES	
GROUP:	0 MG/KG	2000 MG/KG
DAY -8 TO -2		
MEAN	5.4	5.4
S.D.	0.27	0.42
N	5	5
0 TO 1		
MEAN	5.6	5.7
S.D.	1.04	1.20
N	5	5
1 TO 2		
MEAN	5.6	5.6
S.D.	0.33	1.06
N	5	5
2 TO 3		
MEAN	5.5	5.5
S.D.	0.57	0.86
N	5	5
3 TO 4		
MEAN	5.7	5.4
S.D.	1.13	0.44
N	5	5

None significantly different from control group

TABLE 8

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 2

SPONSOR:SYNGENTA SUMMARY OF FOOD CONSUMPTION [G/ANIMAL/DAY]

		MALES	
	GROUP:	0 MG/KG	2000 MG/KG
DAY 4 TO 5			
	MEAN	5.4	5.5
	S.D.	0.29	0.71
	N	5	5
5 TO 6			
	MEAN	5.4	5.2
	S.D.	0.34	0.51
	N	5	5
6 TO 7			
	MEAN	4.9	4.9
	S.D.	0.33	0.41
	N	5	5
7 TO 8			
	MEAN	5.4	5.9
	S.D.	0.26	1.27
	N	5	5
8 TO 9			
	MEAN	4.8	5.7**
	S.D.	0.24	0.46
	N	5	5

** = Significantly different from the control group at 0.01 using Dunnett’s test

TABLE 8

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 3

SPONSOR:SYNGENTA SUMMARY OF FOOD CONSUMPTION [G/ANIMAL/DAY]

	MALES	
GROUP:	0 MG/KG	2000 MG/KG
DAY 9 TO 10		
MEAN	5.6	6.1
S.D.	0.55	0.47
N	5	5
10 TO 11		
MEAN	6.5	6.5
S.D.	0.67	0.45
N	5	5
11 TO 12		
MEAN	4.4	4.9
S.D.	0.57	0.55
N	5	5
12 TO 13		
MEAN	5.1	5.8*
S.D.	0.18	0.56
N	5	5
13 TO 14		
MEAN	5.7	5.5
S.D.	0.49	1.53
N	5	5

* = Significantly different from the control group at 0.05 using Dunnett’s test

TABLE 8

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 4

SPONSOR:SYNGENTA SUMMARY OF FOOD CONSUMPTION [G/ANIMAL/DAY]

	FEMALES	
GROUP:	0 MG/KG	2000 MG/KG
DAY -8 TO -2		
MEAN	5.2	5.9
S.D.	1.50	1.40
N	5	5
0 TO 1		
MEAN	4.2	5.3
S.D.	0.85	0.46
N	5	3
1 TO 2		
MEAN	5.5	4.4
S.D.	1.17	1.80
N	5	3
2 TO 3		
MEAN	5.7	4.2
S.D.	1.94	1.99
N	5	5
3 TO 4		
MEAN	5.3	4.8
S.D.	1.29	0.82
N	5	5

None significantly different from control group

TABLE 8

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 5

SPONSOR:SYNGENTA SUMMARY OF FOOD CONSUMPTION [G/ANIMAL/DAY]

		FEMALES	
	GROUP:	0 MG/KG	2000 MG/KG
DAY 4 TO 5			
	MEAN	5.7	5.7
	S.D.	0.74	1.21
	N	5	5
5 TO 6			
	MEAN	5.7	6.4
	S.D.	1.02	1.75
	N	5	5
6 TO 7			
	MEAN	4.5	5.2
	S.D.	0.58	0.75
	N	5	4
7 TO 8			
	MEAN	5.5	4.6
	S.D.	0.80	0.81
	N	5	4
8 TO 9			
	MEAN	4.5	4.6
	S.D.	0.45	0.93
	N	4	5

None significantly different from control group

TABLE 8

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 6

SPONSOR:SYNGENTA SUMMARY OF FOOD CONSUMPTION [G/ANIMAL/DAY]

	FEMALES	
GROUP:	0 MG/KG	2000 MG/KG
DAY 9 TO 10		
MEAN	4.9	5.5
S.D.	1.08	2.28
N	5	5
10 TO 11		
MEAN	7.1	7.0
S.D.	1.61	1.09
N	5	4
11 TO 12		
MEAN	5.0	4.7
S.D.	1.27	0.48
N	5	4
12 TO 13		
MEAN	5.8	6.2
S.D.	1.85	1.70
N	5	5
13 TO 14		
MEAN	6.3	6.3
S.D.	0.87	0.80
N	5	5

None significantly different from control group

PBFSTv5.28
11/06/2008

TABLE 9

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 1

SPONSOR:SYNGENTA SUMMARY OF MACROSCOPIC FINDINGS

SCHEDULED NECROPSY

	M A L E	
GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
NO SIGNIFICANT CHANGES OBSERVED - ALL EXAMINED TISSUES	5	5

1- 0 MG/KG 2- 2000 MG/KG

TABLE 9

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 2

SPONSOR:SYNGENTA SUMMARY OF MACROSCOPIC FINDINGS

SCHEDULED NECROPSY

	FEMALE	
GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
KIDNEYS		
-SMALL	0	1
NO SIGNIFICANT CHANGES OBSERVED - ALL EXAMINED TISSUES	5	4

1- 0 MG/KG 2- 2000 MG/KG

PGRSI2v4.07
11/05/2008

TABLE 10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 1

SPONSOR:SYNGENTA SUMMARY OF MICROSCOPIC FINDINGS

----- MALE -----

GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
CECUM		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
COLON		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
DUODENUM		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
ESOPHAGUS		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
ILEUM		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
JEJUNUM		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5

1- 0 MG/KG 2- 2000 MG/KG

TABLE 10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 2

SPONSOR:SYNGENTA SUMMARY OF MICROSCOPIC FINDINGS

----- MALE -----

GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
LYMPH NODE, MAND		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	4	5
-HYPERPLASIA, LYMPHOID	1	0
SEVERE	1	NONE
LYMPH NODE, MES		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
PEYER’S PATCHES		
TOTAL NUMBER EXAMINED	4	5
EXAMINED, UNREMARKABLE	4	5
NOT PRESENT FOR EXAMINATION	1	0
RECTUM		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
SPLEEN		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	4
-HEMATOPOIESIS, EXTRAMEDULLARY	0	1
MILD	NONE	1

1- 0 MG/KG 2- 2000 MG/KG

TABLE 10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 3

SPONSOR:SYNGENTA SUMMARY OF MICROSCOPIC FINDINGS

----- MALE -----

GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
STOMACH, GLAN		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
STOMACH, NON		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
THYMUS		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	3	5
-HEMORRHAGE	2	0
MINIMAL	1	NONE
MILD	1	NONE

1- 0 MG/KG 2- 2000 MG/KG

TABLE 10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 4

SPONSOR:SYNGENTA SUMMARY OF MICROSCOPIC FINDINGS

----- FEMALE -----

GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
CECUM		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
COLON		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
DUODENUM		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
ESOPHAGUS		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	4
-INFILTRATE, LYMPHOCYTE	0	1
MINIMAL	NONE	1
ILEUM		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5

1- 0 MG/KG 2- 2000 MG/KG

TABLE 10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 5

SPONSOR:SYNGENTA SUMMARY OF MICROSCOPIC FINDINGS

	----- FEMALE -----	
GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
JEJUNUM		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
KIDNEYS-A		
TOTAL NUMBER EXAMINED	NA	1
EXAMINED, UNREMARKABLE	NA	0
-BASOPHILIC TUBULES	NA	1
MINIMAL	NA	1
LYMPH NODE, MAND		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
LYMPH NODE, MES		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
PEYER'S PATCHES		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5

1- 0 MG/KG 2- 2000 MG/KG

NA = NOT APPLICABLE

A = KIDNEYS WERE NOT INCLUDED IN THE LIST OF TISSUES TO BE EXAMINED. THE KIDNEYS FROM ANIMAL NO. 2778 WERE EXAMINED INADVERTANTLY

TABLE 10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 6

SPONSOR:SYNGENTA SUMMARY OF MICROSCOPIC FINDINGS

----- FEMALE -----

GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
RECTUM		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
SPLEEN		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
STOMACH, GLAN		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
STOMACH, NON		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
THYMUS		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	4	3
-HEMORRHAGE	1	2
MINIMAL	1	2

1- 0 MG/KG 2- 2000 MG/KG

PHSI2v4.30
12/22/2008
R:04/02/2009

FIGURES SECTION

PROJECT NO.:WIL-639031
SPONSOR:SYNGENTA

FIGURE 1
SUMMARY OF BODY WEIGHTS (G) - MALES



BW v1.00 11/06/2008

PROJECT NO.:WIL-639031
SPONSOR:SYNGENTA

FIGURE 2
SUMMARY OF BODY WEIGHTS (G) - FEMALES



BW v1.00 11/06/2008

APPENDICES SECTION

APPENDIX 1 Certificate of Analysis

Certificate of Analysis

Syngenta Biotechnology, Inc.
Regulatory Science
Research Triangle Park, North Carolina USA

Test Substance	ECRY3.1AB-0208
Date Received/Prepared	6/2008
Study Number	5307-08-13
Active Ingredient	eCry3.1Ab
Event/Production Strain	DH5α
Lab Notebook Reference	SY2207
Solubility	10 mg/ml in 10 mM ammonium bicarbonate buffer pH 10.0, purified water, 10% Ethanol and 10 mM Tris buffer containing 0.4 mM EDTA and 0.1% Tween 20
Working Buffer	10 mM ammonium bicarbonate buffer pH 10.0
Total Protein	92.4%
Densitometry	97.0%
Purity	89.6% eCry3.1Ab in ECRY3.1AB-0208
Glycosylation Analysis	Not determined
Activity	Not determined
Molecular Weight	measured 74832.80 Da; theoretical 74832.66 Da
N-terminal Sequence	Not determined
Storage Conditions	-20 degrees Celsius +/- 8 degrees Celsius
Expiration Date	6/2018

Summary Gel and Western Blot:



General Comments:

This Certificate of Analysis is summarizing data from a study that was performed in compliance with Good Laboratory Practices per 40 CFR Part 160. Raw data, documentation, protocols, protocol ammendments, or reports pertaining to this study are maintained in the Syngenta Biotechnology, Inc. Archives, 3054 Cornwallis Rd., Research Triangle Park, NC USA 27709 in accordance with SOP 1.6.

Study Director: Print Andrea Nelson Signature Andrea Nelson Date Sept. 4, 2008

APPENDIX 2 Pretest Clinical Observations

PRETEST CLINICAL OBSERVATIONS

PROJECT NO.:WIL-639031P A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 1

SPONSOR:SYNGENTA SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

	----- M A L E -----
TABLE RANGE:	09-02-08 TO 09-18-08
GROUP:	1
NORMAL	
-NO SIGNIFICANT CLINICAL OBSERVATIONS	44/16
BODY/INTEGUMENT	
-DERMAL ATONIA	1/ 1
EYES/EARS/NOSE	
-ABNORMAL PUPIL POSITION LEFT EYE	2/ 1
EXCRETA	
-DEFECATION DECREASED	1/ 1
BODY/INTEG III	
-DRIED YELLOW MATERIAL UROGENITAL AREA	2/ 2
SPECIAL II	
-WATER BOTTLE ADDED - POOR BODY CONDITION	4/ 3

1- PRETEST

PRETEST CLINICAL OBSERVATIONS

PROJECT NO.:WIL-639031P A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 2

SPONSOR:SYNGENTA SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE: 09-02-08 TO 09-18-08

GROUP: 1

NORMAL	
-NO SIGNIFICANT CLINICAL OBSERVATIONS	45/15
SPECIAL II	
-WATER BOTTLE ADDED - POOR BODY CONDITION	1/ 1

1- PRETEST

PCSUv4.07
11/05/2008

APPENDIX 3 Animal Room Environmental Conditions

PROJECT NO.:WIL- 639031 TEMPERATURE/HUMIDITY - DAILY SUMMARY REPORT BY STUDY
SPONSOR: SYNGENTA

STUDY SPECIFICATIONS: 639031 DATE IN: 09/02/08 TIME IN: 7:00
DATE OUT: 10/03/08 TIME OUT: 14:00

ROOM SPECIFICATIONS: B ROOM 07 LOW TEMPERATURE °F: 66.0 HIGH TEMPERATURE °F: 76.0 LOW HUMIDITY: 30.0
SPECIES: MOUSE LOW TEMPERATURE °C: 18.9 HIGH TEMPERATURE °C: 24.4 HIGH HUMIDITY: 70.0

	TEMPERATURE		HUMIDITY
DATE	MEAN (°F)	MEAN (°C)	MEAN (%RH)
02-Sep-08	71.5	21.9	53.9
03-Sep-08	71.1	21.7	54.1
04-Sep-08	71.1	21.7	52.8
05-Sep-08	71.1	21.7	53.0
06-Sep-08	70.9	21.6	52.3
07-Sep-08	71.7	22.1	54.7
08-Sep-08	71.4	21.9	54.9
09-Sep-08	71.2	21.8	51.9
10-Sep-08	71.6	22.0	52.4
11-Sep-08	71.2	21.8	51.8
12-Sep-08	71.2	21.8	54.9
13-Sep-08	71.2	21.8	55.3
14-Sep-08	71.4	21.9	54.5
15-Sep-08	71.0	21.7	51.8
16-Sep-08	71.8	22.1	54.9
17-Sep-08	71.7	22.1	51.6
18-Sep-08	71.2	21.8	51.6
19-Sep-08	71.3	21.8	51.6
20-Sep-08	71.0	21.7	54.7
21-Sep-08	71.4	21.9	55.2
22-Sep-08	71.6	22.0	55.2
23-Sep-08	71.6	22.0	53.1
24-Sep-08	71.1	21.7	54.1

NOTE: + = VALUE WAS GREATER THAN HIGH RANGE
\- = VALUE WAS LESS THAN LOW RANGE
NOTE: MEANS REPRESENT THE MEAN OF THE DAILY VALUES

REPORT 4
VERSION 1.09
11/6/2008 13:47

STUDY SPECIFICATIONS: 639031 DATE IN: 09/02/08 TIME IN: 7:00
DATE OUT: 10/03/08 TIME OUT: 14:00

ROOM SPECIFICATIONS: B ROOM 07 LOW TEMPERATURE °F: 66.0 HIGH TEMPERATURE °F: 76.0 LOW HUMIDITY: 30.0
SPECIES: MOUSE LOW TEMPERATURE °C: 18.9 HIGH TEMPERATURE °C: 24.4 HIGH HUMIDITY: 70.0

	TEMPERATURE		HUMIDITY
DATE	MEAN (°F)	MEAN (°C)	MEAN (%RH)
25-Sep-08	71.7	22.0	51.5
26-Sep-08	71.3	21.8	51.5
27-Sep-08	71.1	21.7	51.8
28-Sep-08	71.1	21.7	51.8
29-Sep-08	71.3	21.8	51.9
30-Sep-08	71.1	21.7	51.7
01-Oct-08	71.9	22.1	47.8
02-Oct-08	71.4	21.9	43.2
03-Oct-08	71.7	22.1	46.7

GRAND STATS	MEAN	MIN	MAX
TEMPERATURE °F	71.3	70.9	71.9
TEMPERATURE °C	21.9	21.6	22.1
HUMIDITY (%RH)	52.4	43.2	55.3
N DAYS	32		

ROOM SPECIFICATIONS:	B ROOM 07		
SPECIES:	MOUSE		
LOW TEMPERATURE:	66.0	DATE IN:	09/02/08
HIGH TEMPERATURE:	76.0	TIME IN:	7:00
LOW HUMIDITY:	30.0	DATE OUT:	10/03/08
HIGH HUMIDITY:	70.0	TIME OUT:	14:00

ROOM B ROOM 07 SUMMARY

	TEMPERATURE	HUMIDITY
MEAN	71.3	52.5
MIN	68.5	36.2
MAX	75.8	67.6
SD	1.47	4.51
N SAMPLES	750	750
FIRST DAY	09/02/08	
LAST DAY	10/03/08	
N DAYS	32	

NOTE: TEMPERATURE UNITS = DEGREES FAHRENHEIT
HUMIDITY UNITS = % RELATIVE HUMIDITY
NOTE: MEANS REPRESENT THE MEAN OF ALL VALUES

STUDY 639031 SUMMARY

MEAN	71.3	52.5
MIN	68.5	36.2
MAX	75.8	67.6
SD	1.47	4.51
N SAMPLES	750	750
FIRST DAY	09/02/08	
LAST DAY	10/03/08	
N DAYS	32	

NOTE: TEMPERATURE UNITS = DEGREES FAHRENHEIT
HUMIDITY UNITS = % RELATIVE HUMIDITY
NOTE: MEANS REPRESENT THE MEAN OF ALL VALUES

APPENDIX 4 Pathology Report (WIL Research Laboratories, LLC)

ECRY3.1AB-0208: SINGLE-DOSE ORAL (GAVAGE) TOXICITY STUDY IN MICE WITH A 14-DAY OBSERVATION PERIOD

PATHOLOGY REPORT

Pathology Department

WIL Research Laboratories, LLC

TABLE OF CONTENTS

1. INTRODUCTION

The objective of this study was to evaluate the potential toxicity of ECRY3.1AB-0208 when administered as a single dose orally by gavage to mice, followed by a 14-day observation period to assess the reversibilty, persistence, or delayed occurrence of any toxic effects.

2. STUDY DESIGN

Male and female Crl:CD-1 (ICR) mice were administered ECRY3.1AB-0208 via oral gavage once as indicated in the following table. The dose volume was 10 mL/kg for all groups.

Group Number	Test Substance	Dosage Level (mg/kg)	Number of Animals [b] Males	Females
1	Vehicle [a]	0	5	5
2	ECRY3.1AB-0208	2000	5	5

[a] = The vehicle was 0.5% w/v carboxymethyl cellulose (medium viscosity grade).
[b] = All animals were necropsied after a minimum of 14-day observation period.

3. METHODS

3.1. ANATOMIC PATHOLOGY

3.1.1. MACROSCOPIC EXAMINATION

Complete postmortem examinations were performed on all animals at the scheduled necropsy. Animals euthanized at the scheduled necropsy were euthanized by carbon dioxide inhalation and exsanguinated. At the time of necropsy, the following tissues and organs were collected and placed in 10% neutral-buffered formalin fixative unless otherwise noted:

Adrenals (2)
Aorta
Bone with marrow
  Femur with joint
  Sternum
Bone marrow smear [a]
Brain
  Cerebrum (2 levels)
  Cerebellum with pons/medulla
Cervix
Epididymides (2) [b]
Eyes with optic nerves (2) [c]
Gallbladder
Gastrointestinal tract
  Esophagus *
  Stomach *
  Duodenum *
  Jejunum *
  Peyer's patches *
  Ileum *
  Cecum *
  Colon *
  Rectum *
Heart
Kidneys (2)
Liver
Lungs (fixed by inflation with fixative)
Lymph node
  Mandibular *
  Mesenteric *
Ovaries (2) with oviducts
Pancreas
Peripheral nerve (sciatic)
Pituitary
Prostate
Salivary glands [mandibular (2)]
Seminal vesicles (2)
Skeletal muscle (rectus femoris)
Skin with mammary gland [d]
Spinal cord (cervical, thoracic, lumbar)
Spleen *
Testes (2) [b]
Thymus *
Thyroid [with parathyroids if present (2)]
Trachea
Urinary bladder
Uterus
Vagina
All gross lesions (when possible) *

[a] - Bone marrow smears were obtained at the scheduled necropsy, but not placed in formalin; slides were examined only if scientifically warranted.
[b] - Fixed in Bouin's solution
[c] - Fixed in Davidson's solution
[d] - For females; a corresponding section of skin was collected from the same anatomic area for males
* - Tissues processed for histopathological examination from all animals at the scheduled necropsy.

3.1.2. MICROSCOPIC EXAMINATION

Microscopic examination of routinely prepared hematoxylin-eosin stained paraffin sections was performed on selected tissues collected at necropsy, as identified above, from all

animals. Stained histologic sections were examined by light microscopy and observations were entered in the WIL Toxicology Data Management System (WTDMS™) by the pathologist. All gross necropsy observations were addressed. Histologic sections were of adequate size and quality for detailed evaluation. The number of tissues examined from each dosage group may not necessarily equal the number of animals included in the group due to sectioning difficulties. The number of missing tissues was negligible and did not interfere with detection of test substance-related histologic alterations in the study. Histopathologic lesions were classified using standard published terminology to the extent possible. The WTDMS™ histopathology tables contain all of the recorded data and serve as the basis for this narrative report.

4. RESULTS

4.1. SURVIVAL

All mice survived until the scheduled necropsy.

4.2. GROSS OBSERVATIONS

Review of the gross necropsy observations revealed no observations that were considered to be associated with administration of the test substance.

4.3. HISTOLOGIC CHANGES

4.3.1. CHANGES ASSOCIATED WITH TEST SUBSTANCE ADMINISTRATION

There were no histologic changes associated with test substance administration.

All histologic changes were considered to be incidental findings or related to some aspect of experimental manipulation other than administration of the test substance. There was no test substance-related alteration in the prevalence, severity or histologic character of those incidental tissue alterations.

5. CONCLUSIONS

The objective of this study was to evaluate the potential toxicity of ECRY3.1AB-0208 when administered as a single dose orally by gavage to mice, followed by a 14-day observation period. Male and female Crl:CD-1 (ICR) mice (5/sex/group) were administered ECRY3.1AB-0208 via oral gavage once at a dosage of either 0 or 2000 mg/kg. All mice survived to the scheduled necropsy. There were no gross observations associated with the administration of the test substance. Microscopic evaluation was done for the esophagus, stomach, intestinal tract, and lymphoid organs (mandibular and mesenteric lymph nodes, spleen and thymus). There were no histologic changes associated with the administration of the test substance. Administration of a single dose of 2000 mg/kg ECRY3.1AB-0208 by gavage to Crl:CD-1 (ICR) mice followed by a 14-day observation period resulted in no test substance-related gross or histologic alterations.

6. REPORT SUBMISSION

Report Submitted By:

Ann Radovsky 31 March 2009

Ann Radovsky, DVM, PhD, DACVP, DABT Date
Study Pathologist

Report Reviewed By:

G.A. Parker 1 Apr 2009

George A. Parker, DVM, PhD, DACVP, DABT Date
Reviewing Pathologist

APPENDIX 5 Individual Animal Data

TABLE A1

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 1
SPONSOR:SYNGENTA INDIVIDUAL SURVIVAL AND DISPOSITION

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH	DAYS ON STUDY
2751	M	0 MG/KG	SCHEDULED EUTHANASIA	11	03-OCT-08	14
2754	M	0 MG/KG	SCHEDULED EUTHANASIA	11	03-OCT-08	14
2755	M	0 MG/KG	SCHEDULED EUTHANASIA	11	03-OCT-08	14
2759	M	0 MG/KG	SCHEDULED EUTHANASIA	11	03-OCT-08	14
2765	M	0 MG/KG	SCHEDULED EUTHANASIA	11	03-OCT-08	14
2752	M	2000 MG/KG	SCHEDULED EUTHANASIA	11	03-OCT-08	14
2753	M	2000 MG/KG	SCHEDULED EUTHANASIA	11	03-OCT-08	14
2757	M	2000 MG/KG	SCHEDULED EUTHANASIA	11	03-OCT-08	14
2763	M	2000 MG/KG	SCHEDULED EUTHANASIA	11	03-OCT-08	14
2766	M	2000 MG/KG	SCHEDULED EUTHANASIA	11	03-OCT-08	14

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (9)

TABLE A1

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 2

SPONSOR:SYNGENTA INDIVIDUAL SURVIVAL AND DISPOSITION

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH	DAYS ON STUDY
2770	F	0 MG/KG	SCHEDULED EUTHANASIA	11	03-OCT-08	14
2774	F	0 MG/KG	SCHEDULED EUTHANASIA	11	03-OCT-08	14
2775	F	0 MG/KG	SCHEDULED EUTHANASIA	11	03-OCT-08	14
2777	F	0 MG/KG	SCHEDULED EUTHANASIA	11	03-OCT-08	14
2780	F	0 MG/KG	SCHEDULED EUTHANASIA	11	03-OCT-08	14
2768	F	2000 MG/KG	SCHEDULED EUTHANASIA	11	03-OCT-08	14
2776	F	2000 MG/KG	SCHEDULED EUTHANASIA	11	03-OCT-08	14
2778	F	2000 MG/KG	SCHEDULED EUTHANASIA	11	03-OCT-08	14
2779	F	2000 MG/KG	SCHEDULED EUTHANASIA	11	03-OCT-08	14
2781	F	2000 MG/KG	SCHEDULED EUTHANASIA	11	03-OCT-08	14

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (9)

PDEADv4.05
11/20/2008

TABLE A2 (DETAILED PHYSICAL EXAMINATIONS/DISPOSITIONS)

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 1

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 0 THROUGH 14

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
2751	M	0 MG/KG	NORMAL	7	7:45	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2751	M	0 MG/KG	DISPOSITION	14	7:29	P	PRIMARY NECROPSY (DAY 14)
2751	M	0 MG/KG	EYES/EARS/NOSE	0	6:26	P	ABNORMAL PUPIL POSITION LEFT EYE
				14	6:56	P	ABNORMAL PUPIL POSITION LEFT EYE
2754	M	0 MG/KG	NORMAL	0	6:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	7:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	6:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2754	M	0 MG/KG	DISPOSITION	14	7:29	P	PRIMARY NECROPSY (DAY 14)
2755	M	0 MG/KG	NORMAL	0	6:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	7:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	6:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2755	M	0 MG/KG	DISPOSITION	14	7:29	P	PRIMARY NECROPSY (DAY 14)
2759	M	0 MG/KG	NORMAL	0	6:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	7:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	6:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2759	M	0 MG/KG	DISPOSITION	14	7:29	P	PRIMARY NECROPSY (DAY 14)
2765	M	0 MG/KG	NORMAL	0	6:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	7:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	6:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2765	M	0 MG/KG	DISPOSITION	14	7:29	P	PRIMARY NECROPSY (DAY 14)
2752	M	2000 MG/KG	NORMAL	0	6:28	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	7:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2752	M	2000 MG/KG	DISPOSITION	14	7:29	P	PRIMARY NECROPSY (DAY 14)
2752	M	2000 MG/KG	BODY/INTEG III	7	7:57	P	DRIED YELLOW MATERIAL UROGENITAL AREA
2753	M	2000 MG/KG	NORMAL	0	6:28	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	7:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	7:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2753	M	2000 MG/KG	DISPOSITION	14	7:29	P	PRIMARY NECROPSY (DAY 14)
2757	M	2000 MG/KG	NORMAL	0	6:28	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE A2 (DETAILED PHYSICAL EXAMINATIONS/DISPOSITIONS)

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 2

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 0 THROUGH 14

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
2757	M	2000 MG/KG	NORMAL	14	7:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2757	M	2000 MG/KG	DISPOSITION	14	7:29	P	PRIMARY NECROPSY (DAY 14)
2757	M	2000 MG/KG	BODY/INTEG III	7	8:00	P	DRIED YELLOW MATERIAL ANOGENITAL AREA
2763	M	2000 MG/KG	NORMAL	0	6:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	8:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	7:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2763	M	2000 MG/KG	DISPOSITION	14	7:29	P	PRIMARY NECROPSY (DAY 14)
2766	M	2000 MG/KG	NORMAL	0	6:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	8:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	7:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2766	M	2000 MG/KG	DISPOSITION	14	7:29	P	PRIMARY NECROPSY (DAY 14)
2770	F	0 MG/KG	NORMAL	0	6:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	7:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	6:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2770	F	0 MG/KG	DISPOSITION	14	7:29	P	PRIMARY NECROPSY (DAY 14)
2774	F	0 MG/KG	NORMAL	0	6:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	7:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	6:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2774	F	0 MG/KG	DISPOSITION	14	7:29	P	PRIMARY NECROPSY (DAY 14)
2775	F	0 MG/KG	NORMAL	0	6:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	7:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	7:00	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2775	F	0 MG/KG	DISPOSITION	14	7:29	P	PRIMARY NECROPSY (DAY 14)
2777	F	0 MG/KG	NORMAL	0	6:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	7:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	7:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2777	F	0 MG/KG	DISPOSITION	14	7:29	P	PRIMARY NECROPSY (DAY 14)
2780	F	0 MG/KG	NORMAL	0	6:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	7:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE A2 (DETAILED PHYSICAL EXAMINATIONS/DISPOSITIONS)

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 3

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 0 THROUGH 14

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
2780	F	0 MG/KG	NORMAL	14	7:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2780	F	0 MG/KG	DISPOSITION	14	7:29	P	PRIMARY NECROPSY (DAY 14)
2768	F	2000 MG/KG	NORMAL	0	6:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	8:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	7:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2768	F	2000 MG/KG	DISPOSITION	14	7:29	P	PRIMARY NECROPSY (DAY 14)
2776	F	2000 MG/KG	NORMAL	0	6:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	8:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	7:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2776	F	2000 MG/KG	DISPOSITION	14	7:29	P	PRIMARY NECROPSY (DAY 14)
2778	F	2000 MG/KG	NORMAL	0	6:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	8:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	7:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2778	F	2000 MG/KG	DISPOSITION	14	7:29	P	PRIMARY NECROPSY (DAY 14)
2779	F	2000 MG/KG	NORMAL	0	6:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	8:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	7:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2779	F	2000 MG/KG	DISPOSITION	14	7:29	P	PRIMARY NECROPSY (DAY 14)
2781	F	2000 MG/KG	NORMAL	0	6:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	8:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	7:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2781	F	2000 MG/KG	DISPOSITION	14	7:29	P	PRIMARY NECROPSY (DAY 14)

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.11
11/20/2008

TABLE A3 (AT TIME OF DOSING OBSERVATIONS)

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 1

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 0 THROUGH 0

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
2751	M	0 MG/KG	NORMAL	0	11:14	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2754	M	0 MG/KG	NORMAL	0	11:14	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2755	M	0 MG/KG	NORMAL	0	11:14	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2759	M	0 MG/KG	NORMAL	0	11:15	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2765	M	0 MG/KG	NORMAL	0	11:15	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2752	M	2000 MG/KG	NORMAL	0	11:20	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2753	M	2000 MG/KG	NORMAL	0	11:20	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2757	M	2000 MG/KG	NORMAL	0	11:20	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2763	M	2000 MG/KG	NORMAL	0	11:21	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2766	M	2000 MG/KG	NORMAL	0	11:21	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2770	F	0 MG/KG	NORMAL	0	11:16	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2774	F	0 MG/KG	NORMAL	0	11:16	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2775	F	0 MG/KG	NORMAL	0	11:16	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2777	F	0 MG/KG	NORMAL	0	11:16	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2780	F	0 MG/KG	NORMAL	0	11:17	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2768	F	2000 MG/KG	NORMAL	0	11:22	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2776	F	2000 MG/KG	NORMAL	0	11:22	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2778	F	2000 MG/KG	NORMAL	0	11:22	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2779	F	2000 MG/KG	NORMAL	0	11:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2781	F	2000 MG/KG	NORMAL	0	11:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.11
11/20/2008

TABLE A4 (POST-DOSING OBSERVATIONS)

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 1

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 0 THROUGH 0

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
				POST-DOSING OBSERVATIONS			
2751	M	0 MG/KG	NORMAL	0	12:24	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	15:17	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2754	M	0 MG/KG	NORMAL	0	12:24	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	15:17	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2755	M	0 MG/KG	NORMAL	0	12:24	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	15:17	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2759	M	0 MG/KG	NORMAL	0	12:24	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	15:17	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2765	M	0 MG/KG	NORMAL	0	12:24	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	15:18	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2752	M	2000 MG/KG	NORMAL	0	12:25	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	15:20	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2753	M	2000 MG/KG	NORMAL	0	12:25	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	15:21	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2757	M	2000 MG/KG	NORMAL	0	12:25	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	15:21	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2763	M	2000 MG/KG	NORMAL	0	12:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	15:21	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2766	M	2000 MG/KG	NORMAL	0	12:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	15:21	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2770	F	0 MG/KG	NORMAL	0	12:24	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	15:18	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2774	F	0 MG/KG	NORMAL	0	12:24	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	15:18	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2775	F	0 MG/KG	NORMAL	0	12:25	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	15:18	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2777	F	0 MG/KG	NORMAL	0	12:25	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	15:18	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2780	F	0 MG/KG	NORMAL	0	12:25	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE A4 (POST-DOSING OBSERVATIONS)

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 0 THROUGH 0

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
				POST-DOSING OBSERVATIONS			
2780	F	0 MG/KG	NORMAL	0	15:18	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2768	F	2000 MG/KG	NORMAL	0	12:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	15:22	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2776	F	2000 MG/KG	NORMAL	0	12:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	15:22	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2778	F	2000 MG/KG	NORMAL	0	12:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	15:22	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2779	F	2000 MG/KG	NORMAL	0	12:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	15:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2781	F	2000 MG/KG	NORMAL	0	12:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	15:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE A5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639031U — A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE — PAGE 1

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
2751	M	0 MG/KG	NORMAL	1	11:34	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	13:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	13:22	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	10:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	14:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	12:19	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	7:38	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	15:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	9:40	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2754	M	0 MG/KG	NORMAL	1	11:34	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	13:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	13:22	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	10:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	14:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	12:19	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	7:38	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	15:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	9:40	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2755	M	0 MG/KG	NORMAL	1	11:34	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	13:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	13:22	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	10:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE A5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639031U — A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE — PAGE 2

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
2755	M	0 MG/KG	NORMAL	6	14:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	12:20	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	7:38	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	15:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	9:40	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2759	M	0 MG/KG	NORMAL	1	11:34	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	13:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	13:22	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	10:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	14:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	12:20	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	7:38	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	15:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	9:40	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2765	M	0 MG/KG	NORMAL	1	11:34	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	13:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	13:22	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	10:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	14:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	12:20	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	7:38	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	15:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE A5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639031U — A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE — PAGE 3

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
2765	M	0 MG/KG	NORMAL	12	7:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	9:40	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2752	M	2000 MG/KG	NORMAL	1	11:35	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	13:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	13:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	10:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	14:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	7:39	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	15:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	9:41	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2752	M	2000 MG/KG	BODY/INTEG III	8	12:22	P	DRIED YELLOW MATERIAL UROGENITAL AREA
				9	8:31	P	DRIED YELLOW MATERIAL UROGENITAL AREA
2753	M	2000 MG/KG	NORMAL	1	11:35	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	13:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	13:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	10:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	14:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	12:22	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:31	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	7:39	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	15:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	9:41	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2757	M	2000 MG/KG	NORMAL	1	11:35	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	13:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	13:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE A5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639031U — A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE — PAGE 4

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
2757	M	2000 MG/KG	NORMAL	4	7:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	10:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	14:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	12:22	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:31	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	7:39	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	15:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	9:41	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2763	M	2000 MG/KG	NORMAL	1	11:35	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	13:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	13:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	10:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	14:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	12:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:32	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	7:39	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	15:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	9:41	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2766	M	2000 MG/KG	NORMAL	1	11:35	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	13:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	13:24	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	10:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	14:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	12:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:32	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE A5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639031U — A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE — PAGE 5

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
2766	M	2000 MG/KG	NORMAL	10	7:39	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	15:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	9:42	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2770	F	0 MG/KG	NORMAL	1	11:34	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	13:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	13:22	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	10:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	14:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	12:20	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	7:38	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	15:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	9:40	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2774	F	0 MG/KG	NORMAL	1	11:34	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	13:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	13:22	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	10:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	14:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	12:21	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	7:38	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	15:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:28	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	9:40	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2775	F	0 MG/KG	NORMAL	1	11:34	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE A5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639031U — A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE — PAGE 6

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
2775	F	0 MG/KG	NORMAL	2	13:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	13:22	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	10:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	14:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	12:21	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	7:38	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	15:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:28	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	9:40	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2777	F	0 MG/KG	NORMAL	1	11:35	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	13:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	13:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	10:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	14:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	12:21	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	7:38	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	15:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:28	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	9:41	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2780	F	0 MG/KG	NORMAL	1	11:35	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	13:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	13:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	10:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	14:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE A5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639031U — A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE — PAGE 7

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
2780	F	0 MG/KG	NORMAL	8	12:21	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	7:38	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	15:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:28	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	9:41	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2768	F	2000 MG/KG	NORMAL	1	11:35	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	13:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	13:24	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	10:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	14:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	12:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:32	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	7:39	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	15:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	9:42	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2776	F	2000 MG/KG	NORMAL	1	11:35	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	13:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	13:24	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	10:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	14:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	12:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:32	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	7:39	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	15:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE A5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639031U — A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE — PAGE 8

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
2776	F	2000 MG/KG	NORMAL	13	9:42	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2778	F	2000 MG/KG	NORMAL	1	11:35	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	13:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	13:24	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	10:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	14:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	12:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:33	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	7:39	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	15:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	9:42	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2779	F	2000 MG/KG	NORMAL	1	11:36	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	13:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	13:24	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	10:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	14:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	12:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:33	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	7:39	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	15:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	9:42	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2781	F	2000 MG/KG	NORMAL	1	11:36	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	13:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	13:25	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE A5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639031U — A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE — PAGE 9

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
2781	F	2000 MG/KG	NORMAL	5	10:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	14:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	12:24	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:33	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	7:39	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	15:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	9:42	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.11
11/20/2008

TABLE A6

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 1

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

MALE GROUP: 0 MG/KG

DAY	-14	-8	-2	0	1	2	3	4
ANIMAL								
2751	26.0	28.5	31.1	30.0	30.9	31.3	31.6	31.9
2754	27.0	27.9	28.8	28.5	28.9	29.0	29.6	30.0
2755	25.9	28.5	30.6	29.2	29.7	31.0	30.6	30.9
2759	32.0	34.3	35.4	34.1	34.3	34.2	34.6	35.1
2765	29.9	31.2	33.7	32.5	33.4	32.8	33.3	33.5
MEAN	28.2	30.1	31.9	30.9	31.4	31.7	31.9	32.3
S.D.	2.69	2.68	2.62	2.36	2.33	1.96	2.02	2.04
N	5	5	5	5	5	5	5	5

TABLE A6

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 2

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

MALE GROUP: 2000 MG/KG

DAY	-14	-8	-2	0	1	2	3	4
ANIMAL								
2752	29.9	32.8	34.1	33.5	34.1	35.1	33.6	34.8
2753	27.1	29.0	31.0	29.9	30.2	30.8	30.4	30.9
2757	29.0	30.9	33.7	32.2	33.6	31.8	33.1	34.6
2763	26.5	28.4	30.1	29.7	30.8	27.7	30.8	31.7
2766	28.0	29.8	31.5	30.7	32.9	31.9	32.2	32.5
MEAN	28.1	30.2	32.1	31.2	32.3	31.5	32.0	32.9
S.D.	1.38	1.74	1.74	1.62	1.73	2.65	1.40	1.74
N	5	5	5	5	5	5	5	5

TABLE A6

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

MALE GROUP: 0 MG/KG

DAY	5	6	7	8	9	10	11	12
ANIMAL								
2751	32.0	31.8	32.5	32.9	33.8	34.0	32.8	33.7
2754	30.0	29.9	30.9	30.6	30.6	29.9	29.9	30.8
2755	31.2	30.8	31.3	31.2	31.5	31.8	31.2	31.5
2759	34.9	33.8	35.3	34.8	35.0	35.0	34.3	34.7
2765	33.2	33.3	33.8	34.2	34.2	34.1	33.7	34.9
MEAN	32.3	31.9	32.8	32.7	33.0	33.0	32.4	33.1
S.D.	1.88	1.64	1.82	1.83	1.88	2.08	1.81	1.87
N	5	5	5	5	5	5	5	5

TABLE A6

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 4

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

MALE GROUP: 2000 MG/KG

DAY	5	6	7	8	9	10	11	12
ANIMAL								
2752	34.8	33.7	34.8	34.3	34.9	33.8	33.8	35.5
2753	30.6	29.9	30.7	29.8	31.1	31.3	31.0	31.3
2757	34.0	33.1	33.7	33.6	33.8	33.7	33.8	34.4
2763	31.5	31.0	32.1	31.4	32.1	31.8	31.4	33.0
2766	32.3	32.1	32.0	32.3	32.7	32.7	32.8	33.5
MEAN	32.6	32.0	32.7	32.3	32.9	32.7	32.6	33.5
S.D.	1.74	1.54	1.60	1.79	1.48	1.11	1.31	1.57
N	5	5	5	5	5	5	5	5

TABLE A6

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 5

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

MALE GROUP: 0 MG/KG

DAY	13	14
ANIMAL		
2751	34.0	33.8
2754	30.5	30.3
2755	31.9	31.5
2759	34.5	33.8
2765	34.1	34.0
MEAN	33.0	32.7
S.D.	1.73	1.68
N	5	5

TABLE A6

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 6

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

MALE GROUP: 2000 MG/KG

DAY	13	14
ANIMAL		
2752	34.7	35.2
2753	30.9	31.5
2757	33.8	34.5
2763	32.4	33.5
2766	33.5	33.4
MEAN	33.1	33.6
S.D.	1.46	1.40
N	5	5

TABLE A6

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

FEMALE GROUP: 0 MG/KG

DAY	-14	-8	-2	0	1	2	3	4
ANIMAL								
2770	21.2	22.6	24.5	23.3	24.5	24.2	25.6	25.6
2774	23.4	25.9	28.9	27.2	28.4	27.1	29.8	29.4
2775	21.3	23.6	25.4	24.8	24.4	23.5	24.7	25.7
2777	21.2	23.4	24.1	23.5	24.6	21.8	24.3	25.5
2780	23.4	23.9	25.3	23.6	24.3	23.9	25.5	25.1
MEAN	22.1	23.9	25.6	24.5	25.2	24.1	26.0	26.3
S.D.	1.19	1.23	1.90	1.63	1.77	1.92	2.20	1.77
N	5	5	5	5	5	5	5	5

TABLE A6

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 8

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

FEMALE GROUP: 2000 MG/KG

DAY	-14	-8	-2	0	1	2	3	4
ANIMAL								
2768	21.2	24.9	25.2	24.3	25.8	26.9	25.9	26.0
2776	20.8	22.2	23.8	22.1	22.4	23.3	23.5	23.2
2778	24.2	26.3	27.2	25.9	27.3	25.9	26.4	27.1
2779	23.1	24.6	25.8	25.0	25.8	25.8	26.8	27.2
2781	21.6	23.3	25.1	23.6	24.4	25.4	24.9	25.3
MEAN	22.2	24.3	25.4	24.2	25.1	25.5	25.5	25.8
S.D.	1.43	1.57	1.23	1.44	1.84	1.33	1.32	1.63
N	5	5	5	5	5	5	5	5

TABLE A6

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

FEMALE GROUP: 0 MG/KG

DAY	5	6	7	8	9	10	11	12
ANIMAL								
2770	25.7	25.4	25.8	25.8	26.1	26.7	27.0	26.8
2774	28.8	29.1	30.6	29.3	29.6	29.7	29.5	29.2
2775	25.0	24.6	25.6	25.7	24.9	26.0	25.3	26.5
2777	25.4	24.6	24.9	25.2	26.1	26.0	25.4	26.8
2780	25.1	25.6	25.7	25.2	25.4	25.5	25.7	25.8
MEAN	26.0	25.9	26.5	26.2	26.4	26.8	26.6	27.0
S.D.	1.59	1.87	2.31	1.73	1.85	1.69	1.77	1.29
N	5	5	5	5	5	5	5	5

TABLE A6

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

FEMALE GROUP: 2000 MG/KG

DAY	5	6	7	8	9	10	11	12
ANIMAL								
2768	26.1	25.9	26.5	25.8	26.0	26.2	25.3	27.1
2776	23.0	23.1	23.8	23.8	23.4	22.8	23.6	23.8
2778	27.6	26.8	26.8	27.4	28.5	28.0	27.4	28.3
2779	27.0	27.1	27.9	27.7	28.0	27.6	26.7	28.3
2781	24.7	24.4	24.9	25.6	25.5	25.3	25.0	26.6
MEAN	25.7	25.5	26.0	26.1	26.3	26.0	25.6	26.8
S.D.	1.85	1.69	1.62	1.57	2.05	2.08	1.49	1.85
N	5	5	5	5	5	5	5	5

TABLE A6

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

FEMALE GROUP: 0 MG/KG

DAY	13	14
ANIMAL		
2770	27.5	26.2
2774	29.8	29.9
2775	25.9	25.7
2777	26.6	26.3
2780	26.2	25.3
MEAN	27.2	26.7
S.D.	1.57	1.84
N	5	5

TABLE A6

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 12

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

FEMALE GROUP: 2000 MG/KG

DAY	13	14
ANIMAL		
2768	27.4	27.1
2776	23.7	24.3
2778	29.2	28.3
2779	27.7	28.5
2781	26.5	26.2
MEAN	26.9	26.9
S.D.	2.04	1.72
N	5	5

PBFTSv4.44
11/20/2008

TABLE A7

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 1

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

MALE GROUP: 0 MG/KG

DAY	-14 TO -8	-8 TO -2	-2 TO 0	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5
ANIMAL								
2751	2.5	2.6	-1.1	0.9	0.4	0.3	0.3	0.1
2754	0.9	0.9	-0.3	0.4	0.1	0.6	0.4	0.0
2755	2.6	2.1	-1.4	0.5	1.3	-0.4	0.3	0.3
2759	2.3	1.1	-1.3	0.2	-0.1	0.4	0.5	-0.2
2765	1.3	2.5	-1.2	0.9	-0.6	0.5	0.2	-0.3
MEAN	1.9	1.8	-1.1	0.6	0.2	0.3	0.3	0.0
S.D.	0.77	0.79	0.44	0.31	0.70	0.40	0.11	0.24
N	5	5	5	5	5	5	5	5

TABLE A7

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

MALE GROUP: 2000 MG/KG

DAY	-14 TO -8	-8 TO -2	-2 TO 0	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5
ANIMAL								
2752	2.9	1.3	-0.6	0.6	1.0	-1.5	1.2	0.0
2753	1.9	2.0	-1.1	0.3	0.6	-0.4	0.5	-0.3
2757	1.9	2.8	-1.5	1.4	-1.8	1.3	1.5	-0.6
2763	1.9	1.7	-0.4	1.1	-3.1	3.1	0.9	-0.2
2766	1.8	1.7	-0.8	2.2	-1.0	0.3	0.3	-0.2
MEAN	2.1	1.9	-0.9	1.1	-0.9	0.6	0.9	-0.3
S.D.	0.46	0.56	0.43	0.74	1.70	1.75	0.49	0.22
N	5	5	5	5	5	5	5	5

TABLE A7

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 3

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

MALE GROUP: 0 MG/KG

DAY	5 TO 6	6 TO 7	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13
ANIMAL								
2751	-0.2	0.7	0.4	0.9	0.2	-1.2	0.9	0.3
2754	-0.1	1.0	-0.3	0.0	-0.7	0.0	0.9	-0.3
2755	-0.4	0.5	-0.1	0.3	0.3	-0.6	0.3	0.4
2759	-1.1	1.5	-0.5	0.2	0.0	-0.7	0.4	-0.2
2765	0.1	0.5	0.4	0.0	-0.1	-0.4	1.2	-0.8
MEAN	-0.3	0.8	0.0	0.3	-0.1	-0.6	0.7	-0.1
S.D.	0.46	0.42	0.41	0.37	0.39	0.44	0.38	0.49
N	5	5	5	5	5	5	5	5

TABLE A7

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

MALE GROUP: 2000 MG/KG

DAY	5 TO 6	6 TO 7	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13
ANIMAL								
2752	-1.1	1.1	-0.5	0.6	-1.1	0.0	1.7	-0.8
2753	-0.7	0.8	-0.9	1.3	0.2	-0.3	0.3	-0.4
2757	-0.9	0.6	-0.1	0.2	-0.1	0.1	0.6	-0.6
2763	-0.5	1.1	-0.7	0.7	-0.3	-0.4	1.6	-0.6
2766	-0.2	-0.1	0.3	0.4	0.0	0.1	0.7	0.0
MEAN	-0.7	0.7	-0.4	0.6	-0.3	-0.1	1.0	-0.5
S.D.	0.35	0.49	0.48	0.42	0.50	0.23	0.63	0.30
N	5	5	5	5	5	5	5	5

TABLE A7

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 5
SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

MALE GROUP: 0 MG/KG

DAY 13 TO 14
ANIMAL
2751 -0.2
2754 -0.2
2755 -0.4
2759 -0.7
2765 -0.1
MEAN -0.3
S.D. 0.24
N 5

TABLE A7

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 6

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

MALE GROUP: 2000 MG/KG

DAY 13 TO 14
ANIMAL
2752 0.5
2753 0.6
2757 0.7
2763 1.1
2766 -0.1
MEAN 0.6
S.D. 0.43
N 5

TABLE A7

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 7

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

FEMALE GROUP: 0 MG/KG

DAY	-14 TO -8	-8 TO -2	-2 TO 0	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5
ANIMAL								
2770	1.4	1.9	-1.2	1.2	-0.3	1.4	0.0	0.1
2774	2.5	3.0	-1.7	1.2	-1.3	2.7	-0.4	-0.6
2775	2.3	1.8	-0.6	-0.4	-0.9	1.2	1.0	-0.7
2777	2.2	0.7	-0.6	1.1	-2.8	2.5	1.2	-0.1
2780	0.5	1.4	-1.7	0.7	-0.4	1.6	-0.4	0.0
MEAN	1.8	1.8	-1.2	0.8	-1.1	1.9	0.3	-0.3
S.D.	0.83	0.84	0.55	0.68	1.01	0.68	0.77	0.36
N	5	5	5	5	5	5	5	5

TABLE A7

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 8

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

FEMALE GROUP: 2000 MG/KG

DAY	-14 TO -8	-8 TO -2	-2 TO 0	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5
ANIMAL								
2768	3.7	0.3	-0.9	1.5	1.1	-1.0	0.1	0.1
2776	1.4	1.6	-1.7	0.3	0.9	0.2	-0.3	-0.2
2778	2.1	0.9	-1.3	1.4	-1.4	0.5	0.7	0.5
2779	1.5	1.2	-0.8	0.8	0.0	1.0	0.4	-0.2
2781	1.7	1.8	-1.5	0.8	1.0	-0.5	0.4	-0.6
MEAN	2.1	1.2	-1.2	1.0	0.3	0.0	0.3	-0.1
S.D.	0.94	0.59	0.38	0.49	1.06	0.80	0.38	0.41
N	5	5	5	5	5	5	5	5

TABLE A7

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

FEMALE GROUP: 0 MG/KG

DAY	5 TO 6	6 TO 7	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13
ANIMAL								
2770	-0.3	0.4	0.0	0.3	0.6	0.3	-0.2	0.7
2774	0.3	1.5	-1.3	0.3	0.1	-0.2	-0.3	0.6
2775	-0.4	1.0	0.1	-0.8	1.1	-0.7	1.2	-0.6
2777	-0.8	0.3	0.3	0.9	-0.1	-0.6	1.4	-0.2
2780	0.5	0.1	-0.5	0.2	0.1	0.2	0.1	0.4
MEAN	-0.1	0.7	-0.3	0.2	0.4	-0.2	0.4	0.2
S.D.	0.53	0.58	0.64	0.61	0.49	0.45	0.80	0.56
N	5	5	5	5	5	5	5	5

TABLE A7

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

FEMALE GROUP: 2000 MG/KG

DAY	5 TO 6	6 TO 7	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13
ANIMAL								
2768	-0.2	0.6	-0.7	0.2	0.2	-0.9	1.8	0.3
2776	0.1	0.7	0.0	-0.4	-0.6	0.8	0.2	-0.1
2778	-0.8	0.0	0.6	1.1	-0.5	-0.6	0.9	0.9
2779	0.1	0.8	-0.2	0.3	-0.4	-0.9	1.6	-0.6
2781	-0.3	0.5	0.7	-0.1	-0.2	-0.3	1.6	-0.1
MEAN	-0.2	0.5	0.1	0.2	-0.3	-0.4	1.2	0.1
S.D.	0.37	0.31	0.58	0.56	0.32	0.70	0.66	0.56
N	5	5	5	5	5	5	5	5

TABLE A7

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 11
SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

FEMALE GROUP: 0 MG/KG

DAY 13 TO 14	
ANIMAL	
2770	-1.3
2774	0.1
2775	-0.2
2777	-0.3
2780	-0.9
MEAN	-0.5
S.D.	0.57
N	5

TABLE A7

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 12

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

FEMALE GROUP: 2000 MG/KG

DAY 13 TO 14

ANIMAL	
2768	-0.3
2776	0.6
2778	-0.9
2779	0.8
2781	-0.3
MEAN	0.0
S.D.	0.70
N	5

PBFTSv4.44
11/20/2008

TABLE A8

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 1

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

MALE GROUP: 0 MG/KG

DAY	0 TO 1	0 TO 2	0 TO 3	0 TO 4	0 TO 5	0 TO 6	0 TO 7	0 TO 8
ANIMAL								
2751	0.9	1.3	1.6	1.9	2.0	1.8	2.5	2.9
2754	0.4	0.5	1.1	1.5	1.5	1.4	2.4	2.1
2755	0.5	1.8	1.4	1.7	2.0	1.6	2.1	2.0
2759	0.2	0.1	0.5	1.0	0.8	-0.3	1.2	0.7
2765	0.9	0.3	0.8	1.0	0.7	0.8	1.3	1.7
MEAN	0.6	0.8	1.1	1.4	1.4	1.1	1.9	1.9
S.D.	0.31	0.72	0.44	0.41	0.63	0.85	0.61	0.79
N	5	5	5	5	5	5	5	5

TABLE A8

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 2

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

MALE GROUP: 2000 MG/KG

DAY	0 TO 1	0 TO 2	0 TO 3	0 TO 4	0 TO 5	0 TO 6	0 TO 7	0 TO 8
ANIMAL								
2752	0.6	1.6	0.1	1.3	1.3	0.2	1.3	0.8
2753	0.3	0.9	0.5	1.0	0.7	0.0	0.8	-0.1
2757	1.4	-0.4	0.9	2.4	1.8	0.9	1.5	1.4
2763	1.1	-2.0	1.1	2.0	1.8	1.3	2.4	1.7
2766	2.2	1.2	1.5	1.8	1.6	1.4	1.3	1.6
MEAN	1.1	0.3	0.8	1.7	1.4	0.8	1.5	1.1
S.D.	0.74	1.47	0.54	0.56	0.46	0.63	0.59	0.75
N	5	5	5	5	5	5	5	5

TABLE A8

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 3

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

MALE GROUP: 0 MG/KG

DAY	0 TO 9	0 TO 10	0 TO 11	0 TO 12	0 TO 13	0 TO 14
ANIMAL						
2751	3.8	4.0	2.8	3.7	4.0	3.8
2754	2.1	1.4	1.4	2.3	2.0	1.8
2755	2.3	2.6	2.0	2.3	2.7	2.3
2759	0.9	0.9	0.2	0.6	0.4	-0.3
2765	1.7	1.6	1.2	2.4	1.6	1.5
MEAN	2.2	2.1	1.5	2.3	2.1	1.8
S.D.	1.06	1.23	0.97	1.10	1.33	1.48
N	5	5	5	5	5	5

TABLE A8

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 4

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

MALE GROUP: 2000 MG/KG

DAY	0 TO 9	0 TO 10	0 TO 11	0 TO 12	0 TO 13	0 TO 14
ANIMAL						
2752	1.4	0.3	0.3	2.0	1.2	1.7
2753	1.2	1.4	1.1	1.4	1.0	1.6
2757	1.6	1.5	1.6	2.2	1.6	2.3
2763	2.4	2.1	1.7	3.3	2.7	3.8
2766	2.0	2.0	2.1	2.8	2.8	2.7
MEAN	1.7	1.5	1.4	2.3	1.9	2.4
S.D.	0.48	0.72	0.69	0.73	0.84	0.89
N	5	5	5	5	5	5

TABLE A8

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 5

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

FEMALE GROUP: 0 MG/KG

DAY	0 TO 1	0 TO 2	0 TO 3	0 TO 4	0 TO 5	0 TO 6	0 TO 7	0 TO 8
ANIMAL								
2770	1.2	0.9	2.3	2.3	2.4	2.1	2.5	2.5
2774	1.2	-0.1	2.6	2.2	1.6	1.9	3.4	2.1
2775	-0.4	-1.3	-0.1	0.9	0.2	-0.2	0.8	0.9
2777	1.1	-1.7	0.8	2.0	1.9	1.1	1.4	1.7
2780	0.7	0.3	1.9	1.5	1.5	2.0	2.1	1.6
MEAN	0.8	-0.4	1.5	1.8	1.5	1.4	2.0	1.8
S.D.	0.68	1.09	1.12	0.58	0.82	0.97	1.00	0.60
N	5	5	5	5	5	5	5	5

TABLE A8

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

FEMALE GROUP: 2000 MG/KG

DAY	0 TO 1	0 TO 2	0 TO 3	0 TO 4	0 TO 5	0 TO 6	0 TO 7	0 TO 8
ANIMAL								
2768	1.5	2.6	1.6	1.7	1.8	1.6	2.2	1.5
2776	0.3	1.2	1.4	1.1	0.9	1.0	1.7	1.7
2778	1.4	0.0	0.5	1.2	1.7	0.9	0.9	1.5
2779	0.8	0.8	1.8	2.2	2.0	2.1	2.9	2.7
2781	0.8	1.8	1.3	1.7	1.1	0.8	1.3	2.0
MEAN	1.0	1.3	1.3	1.6	1.5	1.3	1.8	1.9
S.D.	0.49	0.99	0.50	0.44	0.47	0.55	0.78	0.50
N	5	5	5	5	5	5	5	5

TABLE A8

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

FEMALE GROUP: 0 MG/KG

DAY	0 TO 9	0 TO 10	0 TO 11	0 TO 12	0 TO 13	0 TO 14
ANIMAL						
2770	2.8	3.4	3.7	3.5	4.2	2.9
2774	2.4	2.5	2.3	2.0	2.6	2.7
2775	0.1	1.2	0.5	1.7	1.1	0.9
2777	2.6	2.5	1.9	3.3	3.1	2.8
2780	1.8	1.9	2.1	2.2	2.6	1.7
MEAN	1.9	2.3	2.1	2.5	2.7	2.2
S.D.	1.09	0.82	1.14	0.81	1.12	0.87
N	5	5	5	5	5	5

TABLE A8

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

FEMALE GROUP: 2000 MG/KG

DAY	0 TO 9	0 TO 10	0 TO 11	0 TO 12	0 TO 13	0 TO 14
ANIMAL						
2768	1.7	1.9	1.0	2.8	3.1	2.8
2776	1.3	0.7	1.5	1.7	1.6	2.2
2778	2.6	2.1	1.5	2.4	3.3	2.4
2779	3.0	2.6	1.7	3.3	2.7	3.5
2781	1.9	1.7	1.4	3.0	2.9	2.6
MEAN	2.1	1.8	1.4	2.6	2.7	2.7
S.D.	0.69	0.70	0.26	0.62	0.66	0.50
N	5	5	5	5	5	5

PBFTSv4.44
11/20/2008

TABLE A9

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 1

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

MALE GROUP: 0 MG/KG

DAY	-8 TO -2	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6	6 TO 7
ANIMAL								
2751	5.3	6.3	6.1	5.0	5.4	5.0	5.0	5.0
2754	5.1	6.7	5.7	6.4	7.6	5.8	5.5	4.3
2755	5.4	5.0	5.6	5.1	4.9	5.5	5.3	5.0
2759	5.8	5.7	5.3	5.4	5.7	5.4	5.9	5.1
2765	5.6	4.1	5.3	5.8	4.8	5.5	5.2	5.0
MEAN	5.4	5.6	5.6	5.5	5.7	5.4	5.4	4.9
S.D.	0.27	1.04	0.33	0.57	1.13	0.29	0.34	0.33
N	5	5	5	5	5	5	5	5

TABLE A9

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 2

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

MALE GROUP: 2000 MG/KG

DAY	-8 TO -2	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6	6 TO 7
ANIMAL								
2752	5.7	6.2	5.9	6.6	5.8	6.2	5.0	4.8
2753	5.6	5.0	5.2	4.5	5.3	4.6	4.5	4.3
2757	5.7	4.8	7.3	5.2	5.6	5.9	5.3	5.1
2763	4.7	4.9	5.2	5.1	4.7	4.8	5.1	5.0
2766	5.4	7.6	4.5	6.2	5.7	5.8	5.9	5.4
MEAN	5.4	5.7	5.6	5.5	5.4	5.5	5.2	4.9
S.D.	0.42	1.20	1.06	0.86	0.44	0.71	0.51	0.41
N	5	5	5	5	5	5	5	5

TABLE A9

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

MALE GROUP: 0 MG/KG

DAY	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14
ANIMAL							
2751	5.4	5.1	4.8	6.0	4.1	5.0	5.3
2754	5.7	4.9	5.3	7.0	3.8	5.2	5.8
2755	5.1	4.7	6.3	5.6	4.6	5.0	5.3
2759	5.3	4.6	5.7	6.6	4.4	5.0	5.8
2765	5.7	4.5	5.7	7.2	5.3	5.4	6.5
MEAN	5.4	4.8	5.6	6.5	4.4	5.1	5.7
S.D.	0.26	0.24	0.55	0.67	0.57	0.18	0.49
N	5	5	5	5	5	5	5

TABLE A9

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

MALE GROUP: 2000 MG/KG

DAY	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14
ANIMAL							
2752	8.0	5.0	6.7	6.2	5.7	5.3	3.2
2753	5.8	6.2	6.1	6.7	4.2	5.1	4.9
2757	4.9	6.0	5.4	6.9	4.9	5.9	5.9
2763	4.9	5.7	6.0	5.8	4.7	6.5	6.5
2766	6.0	5.8	6.2	6.7	5.1	6.0	7.1
MEAN	5.9	5.7	6.1	6.5	4.9	5.8	5.5
S.D.	1.27	0.46	0.47	0.45	0.55	0.56	1.53
N	5	5	5	5	5	5	5

TABLE A9

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

FEMALE GROUP: 0 MG/KG

DAY	-8 TO -2	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6	6 TO 7
ANIMAL								
2770	7.8	4.1	6.2	5.4	7.4	6.8	5.3	3.9
2774	5.2	5.6	7.0	5.3	5.5	5.5	6.4	5.2
2775	4.1	3.4	3.9	9.0	4.3	4.9	5.0	4.7
2777	4.4	3.7	5.2	4.0	4.2	5.2	4.8	3.9
2780	4.6	4.2	5.2	4.7	5.1	5.9	7.2	4.8
MEAN	5.2	4.2	5.5	5.7	5.3	5.7	5.7	4.5
S.D.	1.50	0.85	1.17	1.94	1.29	0.74	1.02	0.58
N	5	5	5	5	5	5	5	5

TABLE A9

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 6

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

FEMALE GROUP: 2000 MG/KG

DAY	-8 TO -2	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6	6 TO 7
ANIMAL								
2768	6.7	4.8	2.4	3.9	4.2	7.7	9.4	NA
2776	4.6	5.7	5.8	5.2	4.2	4.6	5.0	4.7
2778	6.7	NA	NA	1.8	4.7	5.8	6.5	4.9
2779	4.1	5.4	5.1	3.1	4.9	4.9	5.4	4.8
2781	7.2	NA	NA	7.0	6.2	5.6	5.9	6.3
MEAN	5.9	5.3	4.4	4.2	4.8	5.7	6.4	5.2
S.D.	1.40	0.46	1.80	1.99	0.82	1.21	1.75	0.75
N	5	3	3	5	5	5	5	4

NA = NOT APPLICABLE

TABLE A9

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 7

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

FEMALE GROUP: 0 MG/KG

DAY	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14
ANIMAL							
2770	6.2	NA	3.1	6.9	4.0	4.7	7.7
2774	6.5	4.5	5.9	7.3	4.7	5.7	6.0
2775	4.9	4.4	5.3	5.3	4.4	4.2	6.4
2777	5.0	5.0	4.7	6.2	4.6	5.3	6.3
2780	4.8	3.9	5.4	9.6	7.2	8.9	5.3
MEAN	5.5	4.5	4.9	7.1	5.0	5.8	6.3
S.D.	0.80	0.45	1.08	1.61	1.27	1.85	0.87
N	5	4	5	5	5	5	5

NA = NOT APPLICABLE

TABLE A9

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

FEMALE GROUP: 2000 MG/KG

DAY	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14
ANIMAL							
2768	3.5	3.2	2.0	NA	NA	8.8	6.1
2776	4.5	4.9	6.8	6.1	4.2	5.1	5.9
2778	NA	5.2	5.3	6.8	4.7	6.8	5.7
2779	4.9	4.3	5.2	6.6	4.4	4.4	7.7
2781	5.4	5.6	8.1	8.6	5.3	6.0	6.1
MEAN	4.6	4.6	5.5	7.0	4.7	6.2	6.3
S.D.	0.81	0.93	2.28	1.09	0.48	1.70	0.80
N	4	5	5	4	4	5	5

NA = NOT APPLICABLE

PBFTSv4.44
11/20/2008

TABLE A10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 1
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

ANIMAL NO. 2751 GROUP 1: 0 MG/KG MALE SCHEDULED EUTH 10/03/08 DATE OF DEATH: 10/03/08 STUDY DAY: 14

NO SIGNIFICANT CHANGES OBSERVED

	GRADE			
GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.
	GALLBLADDER	HEART	ILEUM	JEJUNUM
	KIDNEYS	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES
	LUNGS	NERVE, SCIATIC	PANCREAS	PITUITARY
	PROSTATE	RECTUM	SPINAL CORD	SAL. GLAND MAND
	STOMACH	SKELETAL MUSCLE	SKIN	SPLEEN
	SEMINAL VESICLES	TESTES	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LYMPH NODE, MAND	LYMPH NODE, MES
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE A10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 2
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

ANIMAL NO. 2754 GROUP 1: 0 MG/KG MALE SCHEDULED EUTH 10/03/08 DATE OF DEATH: 10/03/08 STUDY DAY: 14

NO SIGNIFICANT CHANGES OBSERVED

	GRADE			
GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.
	GALLBLADDER	HEART	ILEUM	JEJUNUM
	KIDNEYS	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES
	LUNGS	NERVE, SCIATIC	PANCREAS	PITUITARY
	PROSTATE	RECTUM	SPINAL CORD	SAL. GLAND MAND
	STOMACH	SKELETAL MUSCLE	SKIN	SPLEEN
	SEMINAL VESICLES	TESTES	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LYMPH NODE, MAND	LYMPH NODE, MES
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE A10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

ANIMAL NO. 2755 GROUP 1: 0 MG/KG MALE SCHEDULED EUTH 10/03/08 DATE OF DEATH: 10/03/08 STUDY DAY: 14

					GRADE
THYMUS	MICRO: HEMORRHAGE				2
NO SIGNIFICANT CHANGES OBSERVED	GROSS: ADRENAL GLANDS	AORTA	STERNUM	FEMUR	
	JOINT	BRAIN	CECUM	COLON	
	DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.	
	GALLBLADDER	HEART	ILEUM	JEJUNUM	
	KIDNEYS	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	
	LUNGS	NERVE, SCIATIC	PANCREAS	PITUITARY	
	PROSTATE	RECTUM	SPINAL CORD	SAL. GLAND MAND	
	STOMACH	SKELETAL MUSCLE	SKIN	SPLEEN	
	SEMINAL VESICLES	TESTES	PEYER'S PATCHES	THYROID GLANDS	
	THYMUS	TRACHEA	URINARY BLADDER		
	MICRO: CECUM	COLON	DUODENUM	ESOPHAGUS	
	ILEUM	JEJUNUM	LYMPH NODE, MAND	LYMPH NODE, MES	
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN	
	PEYER'S PATCHES				

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE A10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

ANIMAL NO. 2759 GROUP 1: 0 MG/KG MALE SCHEDULED EUTH 10/03/08 DATE OF DEATH: 10/03/08 STUDY DAY: 14

			GRADE
THYMUS	MICRO: HEMORRHAGE		1
NO SIGNIFICANT CHANGES OBSERVED	GROSS:		

ADRENAL GLANDS	AORTA	STERNUM	FEMUR
JOINT	BRAIN	CECUM	COLON
DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.
GALLBLADDER	HEART	ILEUM	JEJUNUM
KIDNEYS	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES
LUNGS	NERVE, SCIATIC	PANCREAS	PITUITARY
PROSTATE	RECTUM	SPINAL CORD	SAL. GLAND MAND
STOMACH	SKELETAL MUSCLE	SKIN	SPLEEN
SEMINAL VESICLES	TESTES	PEYER'S PATCHES	THYROID GLANDS
THYMUS	TRACHEA	URINARY BLADDER	

MICRO:

CECUM	COLON	DUODENUM	ESOPHAGUS
ILEUM	JEJUNUM	LYMPH NODE, MAND	LYMPH NODE, MES
RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN

NOT PRESENT FOR EXAMINATION

MICRO:PEYER'S PATCHES

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE A10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 5
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

ANIMAL NO. 2765 GROUP 1: 0 MG/KG MALE SCHEDULED EUTH 10/03/08 DATE OF DEATH: 10/03/08 STUDY DAY: 14

			GRADE
	LYMPH NODE, MAND	MICRO: HYPERPLASIA, LYMPHOID UNILATERAL	4
	NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.
	GALLBLADDER	HEART	ILEUM	JEJUNUM
	KIDNEYS	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES
	LUNGS	NERVE, SCIATIC	PANCREAS	PITUITARY
	PROSTATE	RECTUM	SPINAL CORD	SAL. GLAND MAND
	STOMACH	SKELETAL MUSCLE	SKIN	SPLEEN
	SEMINAL VESICLES	TESTES	PEYER’S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LYMPH NODE, MES	RECTUM
	STOMACH, GLAN	STOMACH, NON	SPLEEN	PEYER’S PATCHES
	THYMUS			

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE A10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 6
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

ANIMAL NO. 2752 GROUP 2: 2000 MG/KG MALE SCHEDULED EUTH 10/03/08 DATE OF DEATH: 10/03/08 STUDY DAY: 14

					GRADE
NO SIGNIFICANT CHANGES OBSERVED	GROSS: ADRENAL GLANDS	AORTA	STERNUM	FEMUR	
	JOINT	BRAIN	CECUM	COLON	
	DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.	
	GALLBLADDER	HEART	ILEUM	JEJUNUM	
	KIDNEYS	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	
	LUNGS	NERVE, SCIATIC	PANCREAS	PITUITARY	
	PROSTATE	RECTUM	SPINAL CORD	SAL. GLAND MAND	
	STOMACH	SKELETAL MUSCLE	SKIN	SPLEEN	
	SEMINAL VESICLES	TESTES	PEYER'S PATCHES	THYROID GLANDS	
	THYMUS	TRACHEA	URINARY BLADDER		
	MICRO: CECUM	COLON	DUODENUM	ESOPHAGUS	
	ILEUM	JEJUNUM	LYMPH NODE, MAND	LYMPH NODE, MES	
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN	
	PEYER'S PATCHES	THYMUS			

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE A10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 7
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

ANIMAL NO. 2753 GROUP 2: 2000 MG/KG MALE SCHEDULED EUTH 10/03/08 DATE OF DEATH: 10/03/08 STUDY DAY: 14

		GRADE			
NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
		JOINT	BRAIN	CECUM	COLON
		DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.
		GALLBLADDER	HEART	ILEUM	JEJUNUM
		KIDNEYS	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES
		LUNGS	NERVE, SCIATIC	PANCREAS	PITUITARY
		PROSTATE	RECTUM	SPINAL CORD	SAL. GLAND MAND
		STOMACH	SKELETAL MUSCLE	SKIN	SPLEEN
		SEMINAL VESICLES	TESTES	PEYER'S PATCHES	THYROID GLANDS
		THYMUS	TRACHEA	URINARY BLADDER	
	MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
		ILEUM	JEJUNUM	LYMPH NODE, MAND	LYMPH NODE, MES
		RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
		PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE A10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 8
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

ANIMAL NO. 2757 GROUP 2: 2000 MG/KG MALE SCHEDULED EUTH 10/03/08 DATE OF DEATH: 10/03/08 STUDY DAY: 14

						GRADE
SPLEEN	MICRO: HEMATOPOIESIS, EXTRAMEDULLARY					2
NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR	
		JOINT	BRAIN	CECUM	COLON	
		DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.	
		GALLBLADDER	HEART	ILEUM	JEJUNUM	
		KIDNEYS	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	
		LUNGS	NERVE, SCIATIC	PANCREAS	PITUITARY	
		PROSTATE	RECTUM	SPINAL CORD	SAL. GLAND MAND	
		STOMACH	SKELETAL MUSCLE	SKIN	SPLEEN	
		SEMINAL VESICLES	TESTES	PEYER'S PATCHES	THYROID GLANDS	
		THYMUS	TRACHEA	URINARY BLADDER		
	MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS	
		ILEUM	JEJUNUM	LYMPH NODE, MAND	LYMPH NODE, MES	
		RECTUM	STOMACH, GLAN	STOMACH, NON	PEYER'S PATCHES	
		THYMUS				

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE A10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 9
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

ANIMAL NO. 2763 GROUP 2: 2000 MG/KG MALE SCHEDULED EUTH 10/03/08 DATE OF DEATH: 10/03/08 STUDY DAY: 14

		GRADE			
NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
		JOINT	BRAIN	CECUM	COLON
		DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.
		GALLBLADDER	HEART	ILEUM	JEJUNUM
		KIDNEYS	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES
		LUNGS	NERVE, SCIATIC	PANCREAS	PITUITARY
		PROSTATE	RECTUM	SPINAL CORD	SAL. GLAND MAND
		STOMACH	SKELETAL MUSCLE	SKIN	SPLEEN
		SEMINAL VESICLES	TESTES	PEYER'S PATCHES	THYROID GLANDS
		THYMUS	TRACHEA	URINARY BLADDER	
	MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
		ILEUM	JEJUNUM	LYMPH NODE, MAND	LYMPH NODE, MES
		RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
		PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE A10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

ANIMAL NO. 2766 GROUP 2: 2000 MG/KG MALE SCHEDULED EUTH 10/03/08 DATE OF DEATH: 10/03/08 STUDY DAY: 14

					GRADE
NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
		JOINT	BRAIN	CECUM	COLON
		DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.
		GALLBLADDER	HEART	ILEUM	JEJUNUM
		KIDNEYS	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES
		LUNGS	NERVE, SCIATIC	PANCREAS	PITUITARY
		PROSTATE	RECTUM	SPINAL CORD	SAL. GLAND MAND
		STOMACH	SKELETAL MUSCLE	SKIN	SPLEEN
		SEMINAL VESICLES	TESTES	PEYER'S PATCHES	THYROID GLANDS
		THYMUS	TRACHEA	URINARY BLADDER	
	MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
		ILEUM	JEJUNUM	LYMPH NODE, MAND	LYMPH NODE, MES
		RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
		PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE A10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

ANIMAL NO. 2770 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 10/03/08 DATE OF DEATH: 10/03/08 STUDY DAY: 14

NO SIGNIFICANT CHANGES OBSERVED

GRADE				
GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS
	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS	OVARIES
	PANCREAS	PITUITARY	RECTUM	SPINAL CORD
	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
	SPLEEN	PEYER'S PATCHES	THYROID GLANDS	THYMUS
	TRACHEA	URINARY BLADDER	UTERUS	VAGINA
	CERVIX			
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LYMPH NODE, MAND	LYMPH NODE, MES
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE A10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 12
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

ANIMAL NO. 2774 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 10/03/08 DATE OF DEATH: 10/03/08 STUDY DAY: 14

			GRADE
THYMUS	MICRO: HEMORRHAGE		1
NO SIGNIFICANT CHANGES OBSERVED	GROSS:		

ADRENAL GLANDS	AORTA	STERNUM	FEMUR	
JOINT	BRAIN	CECUM	COLON	
DUODENUM	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER	
HEART	ILEUM	JEJUNUM	KIDNEYS	
LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS	
MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS	OVARIES	
PANCREAS	PITUITARY	RECTUM	SPINAL CORD	
SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN	
SPLEEN	PEYER’S PATCHES	THYROID GLANDS	THYMUS	
TRACHEA	URINARY BLADDER	UTERUS	VAGINA	
CERVIX				

MICRO:

CECUM	COLON	DUODENUM	ESOPHAGUS
ILEUM	JEJUNUM	LYMPH NODE, MAND	LYMPH NODE, MES
RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
PEYER’S PATCHES			

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE A10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

ANIMAL NO. 2775 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 10/03/08 DATE OF DEATH: 10/03/08 STUDY DAY: 14

NO SIGNIFICANT CHANGES OBSERVED

GRADE				
GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS
	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS	OVARIES
	PANCREAS	PITUITARY	RECTUM	SPINAL CORD
	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
	SPLEEN	PEYER'S PATCHES	THYROID GLANDS	THYMUS
	TRACHEA	URINARY BLADDER	UTERUS	VAGINA
	CERVIX			
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LYMPH NODE, MAND	LYMPH NODE, MES
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE A10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 14
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

ANIMAL NO. 2777 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 10/03/08 DATE OF DEATH: 10/03/08 STUDY DAY: 14

				GRADE
GENERAL COMMENT	GROSS: ORGAN DAMAGED AT NECROPSY OPTIC NERVE, SIDE DESIGNATION UNKNOWN			P
NO SIGNIFICANT CHANGES OBSERVED	GROSS: ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS
	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS	OVARIES
	PANCREAS	PITUITARY	RECTUM	SPINAL CORD
	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
	SPLEEN	PEYER'S PATCHES	THYROID GLANDS	THYMUS
	TRACHEA	URINARY BLADDER	UTERUS	VAGINA
	CERVIX			
	MICRO: CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LYMPH NODE, MAND	LYMPH NODE, MES
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE A10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 15
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

ANIMAL NO. 2780 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 10/03/08 DATE OF DEATH: 10/03/08 STUDY DAY: 14

NO SIGNIFICANT CHANGES OBSERVED

				GRADE
GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS
	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS	OVARIES
	PANCREAS	PITUITARY	RECTUM	SPINAL CORD
	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
	SPLEEN	PEYER'S PATCHES	THYROID GLANDS	THYMUS
	TRACHEA	URINARY BLADDER	UTERUS	VAGINA
	CERVIX			
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LYMPH NODE, MAND	LYMPH NODE, MES
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE A10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

ANIMAL NO. 2768 GROUP 2: 2000 MG/KG FEMALE SCHEDULED EUTH 10/03/08 DATE OF DEATH: 10/03/08 STUDY DAY: 14

			GRADE
THYMUS	MICRO: HEMORRHAGE		1
NO SIGNIFICANT CHANGES OBSERVED	GROSS:		

ADRENAL GLANDS	AORTA	STERNUM	FEMUR
JOINT	BRAIN	CECUM	COLON
DUODENUM	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER
HEART	ILEUM	JEJUNUM	KIDNEYS
LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS
MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS	OVARIES
PANCREAS	PITUITARY	RECTUM	SPINAL CORD
SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
SPLEEN	PEYER'S PATCHES	THYROID GLANDS	THYMUS
TRACHEA	URINARY BLADDER	UTERUS	VAGINA
CERVIX			

MICRO:

CECUM	COLON	DUODENUM	ESOPHAGUS
ILEUM	JEJUNUM	LYMPH NODE, MAND	LYMPH NODE, MES
RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
PEYER'S PATCHES			

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE A10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 17
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

ANIMAL NO. 2776 GROUP 2: 2000 MG/KG FEMALE SCHEDULED EUTH 10/03/08 DATE OF DEATH: 10/03/08 STUDY DAY: 14

			GRADE
	ESOPHAGUS	MICRO: INFILTRATE, LYMPHOCYTE IN MUSCLE WALL	1
	NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS
	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS	OVARIES
	PANCREAS	PITUITARY	RECTUM	SPINAL CORD
	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
	SPLEEN	PEYER'S PATCHES	THYROID GLANDS	THYMUS
	TRACHEA	URINARY BLADDER	UTERUS	VAGINA
	CERVIX			
MICRO:	CECUM	COLON	DUODENUM	ILEUM
	JEJUNUM	LYMPH NODE, MAND	LYMPH NODE, MES	RECTUM
	STOMACH, GLAN	STOMACH, NON	SPLEEN	PEYER'S PATCHES
	THYMUS			

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE A10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE PAGE 18
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

ANIMAL NO. 2778 GROUP 2: 2000 MG/KG FEMALE SCHEDULED EUTH 10/03/08 DATE OF DEATH: 10/03/08 STUDY DAY: 14

			GRADE
KIDNEYS	GROSS: SMALL RIGHT		P
^==>	GROSS UNCONFIRMED		
KIDNEYS-A NO SIGNIFICANT CHANGES OBSERVED	MICRO: BASOPHILIC TUBULES		1

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER
	HEART	ILEUM	JEJUNUM	LYMPH NODE, MAND
	LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
	NERVE, SCIATIC	OVIDUCTS	OVARIES	PANCREAS
	PITUITARY	RECTUM	SPINAL CORD	SAL. GLAND MAND
	STOMACH	SKELETAL MUSCLE	SKIN	SPLEEN
	PEYER'S PATCHES	THYROID GLANDS	THYMUS	TRACHEA
	URINARY BLADDER	UTERUS	VAGINA	CERVIX
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LYMPH NODE, MAND	LYMPH NODE, MES
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT
^==> INDICATES MICRO CONFIRMATION OF ABOVE GROSS FINDING

A = KIDNEYS WERE NOT ON THE LIST OF TISSUES TO BE EXAMINED. KIDNEYS FROM ANIMAL NO. 2778 WERE EXAMINED INADVERTANTLY

TABLE A10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

ANIMAL NO. 2779 GROUP 2: 2000 MG/KG FEMALE SCHEDULED EUTH 10/03/08 DATE OF DEATH: 10/03/08 STUDY DAY: 14

					GRADE
NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
		JOINT	BRAIN	CECUM	COLON
		DUODENUM	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER
		HEART	ILEUM	JEJUNUM	KIDNEYS
		LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS
		MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS	OVARIES
		PANCREAS	PITUITARY	RECTUM	SPINAL CORD
		SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
		SPLEEN	PEYER'S PATCHES	THYROID GLANDS	THYMUS
		TRACHEA	URINARY BLADDER	UTERUS	VAGINA
		CERVIX			
	MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
		ILEUM	JEJUNUM	LYMPH NODE, MAND	LYMPH NODE, MES
		RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
		PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE A10

PROJECT NO.:WIL-639031 A SINGLE-DOSE OF ECRY3.1AB-0208 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

ANIMAL NO. 2781 GROUP 2: 2000 MG/KG FEMALE SCHEDULED EUTH 10/03/08 DATE OF DEATH: 10/03/08 STUDY DAY: 14

			GRADE
THYMUS	MICRO: HEMORRHAGE		1
NO SIGNIFICANT CHANGES OBSERVED	GROSS:		

ADRENAL GLANDS	AORTA	STERNUM	FEMUR
JOINT	BRAIN	CECUM	COLON
DUODENUM	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER
HEART	ILEUM	JEJUNUM	KIDNEYS
LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS
MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS	OVARIES
PANCREAS	PITUITARY	RECTUM	SPINAL CORD
SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
SPLEEN	PEYER'S PATCHES	THYROID GLANDS	THYMUS
TRACHEA	URINARY BLADDER	UTERUS	VAGINA
CERVIX			

MICRO:

CECUM	COLON	DUODENUM	ESOPHAGUS
ILEUM	JEJUNUM	LYMPH NODE, MAND	LYMPH NODE, MES
RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
PEYER'S PATCHES			

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

PGRHv4.63
11/20/2008
R:04/02/2009